2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

专利摘要:
The present invention relates to 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the detailed description and their pharmaceutical uses. The compounds of the invention are particularly suitable for the treatment of neurological disorders such as epilepsy.
公开号:KR20020075926A
申请号:KR1020027010960
申请日:2001-02-21
公开日:2002-10-07
发明作者:에드먼드 디페르딩；베노트 켄다；베네딕테 랄레만드；알라인 마타그네；필립페 미첼；패트릭 파사우；파트리스 탈라가
申请人:유씨비 소시에떼아노님；
IPC主号:

专利说明:

PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES [0002] This invention relates to 2-oxo-1-pyrrolidine derivatives,
[2] EP 0 162 036 B1 describes the compound (S) -a-ethyl-2-oxo-1-pyrrolidineacetamide and is well known in the general name levetiracetam.
[3] Levetiracetam, a left-turnover compound, is described as a protective agent for treating and preventing hypoxic and ischemic-type attacks of the central nervous system. Such compounds are also effective in the treatment of epilepsy and as therapeutic indications, their right-handed enantiomers, (R) -a-ethyl-2-oxo-1-pyrrolidone known from EP 0 165 919 B1 (A.J. GOWER et al., Eur. J. Pharmacol., 222 , (1992), 193-203).
[4] Racemic alpha-ethyl-2-oxo-1-pyrrolidineacetamide and its derivatives are known from British Patent No. 1 309 692. U.S. Patent No. 3 459 738 describes derivatives of 2-oxo-1-pyrrolidineacetamide. European Patent 0 645 139 B1 discloses rheu- tilacetam for the therapeutic and / or prophylactic treatment of bipolar disorder, migraine, chronic or neuropathic pain, and one or more compounds which induce nerve suppression mediated by the GABA _A receptor The use of the above compound and the combination of levetiracetam is described.
[5] It has now surprisingly been shown that certain analogs of levetiracetam, especially analogs containing additional substituents in the pyrrolidone ring, significantly enhance the therapeutic properties.
[1] The present invention relates to 2-oxo-1-pyrrolidine derivatives, a process for their preparation, pharmaceutical compositions containing them and their use as medicaments.
[6] In one aspect, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein:
[7]
[8] In this formula,
[9] X is -CA ¹ NR ⁵ R ⁶ , -CA ¹ OR ⁷ , -CA ¹ -R ⁸ or CN;
[10] A ¹ and A ² are independently oxygen, sulfur or -NR ⁹ ;
[11] R ¹ is hydrogen, alkyl, aryl or -CH ₂ -R ^1a , wherein R ^1a is aryl, heterocycle, halogen, hydroxy, amino, nitro or cyano;
[12] R ² , R ³ and R ⁴ are the same or different and each is independently selected from the group consisting of hydrogen, halogen, hydroxy, thiol, amino, nitro, nitrooxy, cyano, azido, carboxy, amido, Alkyl, alkenyl, alkynyl, ester, ether, aryl, heterocycle or oxy derivative, thio derivative, amino derivative, acyl derivative, sulfonyl derivative or sulfinyl derivative;
[13] R ^2a , R ^3a and R ^4a are the same or different and each independently hydrogen, halogen, alkyl, alkenyl, alkynyl or aryl;
[14] R ⁵ , R ⁶ , R ⁷ and R ⁹ are the same or different and each independently is hydrogen, hydroxy, alkyl, aryl, heterocycle or oxy derivative;
[15] R ⁸ is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, heterocycle or thio derivative;
[16] Provided that at least one of R ² , R ³ , R ⁴ , R ^2a , R ^3a and R ^4a is a group other than hydrogen,
[17] When the compound is a mixture of all possible isomers, X is -CONR ⁵ R ⁶ , A ² is oxygen and R ¹ is hydrogen, methyl, ethyl or propyl, the substituents on the pyrrolidine ring may be mono-, Methyl, or mono-ethyl;
[18] ^{R 1, R 2, R 4} , R 2a, R 3a and R ^4a are each hydrogen, A ² is oxygen, X is -CONR ⁵ R ⁶ Ann Wu, R ³ is carboxy, ester, amido road, substituted And is different from a phenyl group optionally substituted at the para position by an oxo-pyrrolidine, a hydroxy, an oxy derivative, an amino, an amino derivative, a methyl, a naphthyl or a halogen atom.
[19] R ¹¹ and R ¹² are the same or different and are each independently selected from the group consisting of amido, alkyl, alkenyl, alkynyl, acyl, ester, ether, aryl, aralkyl, But are not limited to, one or more moieties selected from other groups as described below as substituents for lower alkyl or alkyl, respectively, such as, but not limited to, Lt; / RTI > is optionally substituted by a suitable group.
[20] The term " oxy derivative " as used herein may be defined as including an -OR ¹¹ group as defined above, except that R ¹¹ is an "oxy derivative". Non-limiting examples include alkoxy, alkenyloxy, alkynyloxy, acyloxy, oxyester, oxyamido, alkylsulfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy, Oxy or heterocycleoxy such as pentyloxy, allyloxy, methoxy, ethoxy, phenoxy, benzyloxy, 2-naphthyloxy, 2-pyridyloxy, methylenedioxy, carbonate.
[21] The term "thio derivative" as used herein may be defined as for R ¹¹ includes a group -SR ¹¹ as defined above, except that the "thio derivative". Non-limiting examples include alkylthio, alkenylthio, alkynylthio and arylthio.
[22] As used herein, the term " amino derivative " may be defined as an -NHR ¹¹ or -NR ¹¹ R ¹² group wherein R ¹¹ and R ¹² are as defined above. Non-limiting examples include mono-or di-alkyl-, alkenyl-, alkynyl- and arylamino or mixed amino.
[23] As used herein, the term " acyl derivative " is a radical derived from a carboxylic acid, and may be defined as including a group of the formula R ¹¹ -CO- where R ¹¹ is as defined above or may be hydrogen. Non-limiting examples include formyl, acetyl, propionyl, isobutyryl, valeryl, lauroyl, heptanedioyl, cyclohexanecarbonyl, crotonoyl, fumaroyl, acrylic oil, benzoyl, naphthoyl, furo Yl, nicotinoyl, 4-carboxybutanoyl, oxalyl, ethoxalyl, cysteinyl, oxamoyl.
[24] The term "sulfonyl derivative" as used herein defined may be made as including a group of the formula -SO ₂ -R ¹¹ as defined above, R ¹¹ is other than "sulfonyl derivative". Non-limiting examples include alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl and arylsulfonyl.
[25] The term "sulfinyl derivative" as used herein defined may be made as including R ¹¹ is "sulfinyl derivative" other than the group of the formula -SO-R ¹¹ as defined above. Non-limiting examples include alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl and arylsulfinyl.
[26] As used herein, the term " alkyl " refers to a linear, branched, or cyclic moiety, or a mixture thereof, containing 1-20 carbon atoms, preferably 1-6 carbon atoms for bicyclic alkyl, For alkyl, saturated monovalent hydrocarbon radicals containing from 3 to 6 carbon atoms (in both of the above cases, it is " lower alkyl " unless otherwise stated). The alkyl moiety may be substituted with at least one substituent selected from the group consisting of halogen, hydroxy, thiol, amino, nitro, cyano, thiocyanato, acyl, acyloxy, sulfonyl derivatives, sulfinyl derivatives, alkylamino, carboxy, ester, 1 to 5, independently selected from the group consisting of alkyl, sulfonic acid, sulfonamide, thio derivatives, oxy esters, oxyamido, heterocycle, vinyl, C1-5-alkoxy, C1-6-aryloxy and C6-10- ≪ / RTI >
[27] Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, iso, or tert-butyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, thiol, amino, 2,2-trimethylethyl such as trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl- , 2,2-trichloroethyl.
[28] The term " alkenyl ", as used herein, refers to an alkyl group having one or more double bonds such as ethenyl (= vinyl), 1-methyl-1-ethenyl, 2,2- -Propenyl (= allyl), 1-butenyl, 2-butenyl, 3-butenyl, 4-pentenyl, , 2-hexenyl, and the like, optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, thiol, amino, nitro, cyano, aryl and heterocycle such as mono and di- Branched and unbranched unsaturated hydrocarbon radicals optionally substituted by one or more substituents selected from the group consisting of hydrogen,
[29] The term " alkynyl ", as used herein, refers to an alkyl group containing one or more carbon-carbon triple bonds such as ethynyl, 2-propynyl , Monovalent branched or unbranched hydrocarbon radicals optionally substituted by one or more substituents selected from the group consisting of cyano, aryl and heterocycle such as haloethynyl.
[30] When present as a bridging group, the alkyl, alkenyl and alkynyl are each a linear or branched chain, C1-12, preferably C1-4 alkylene or C2-12, preferably C2-4 alkenylene or -Alkynylene moiety.
[31] (E.g., " n-propyl ", " secondary-butyl ") where the branched derivatives are conventionally modified by prefixes such as "n" .
[32] The term " aryl ", as used herein, refers to an aromatic hydrocarbon comprising from one to three rings and containing from 6 to 30 carbon atoms by removal of one hydrogen, such as halogen, hydroxy, thiol, amino, Alkyl, alkoxy, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, alkylthio, Phenyl and naphthyl, each of which is optionally substituted by 1 to 5 substituents independently selected from lower alkyl, halogen, lower alkyl, lower alkoxy, lower alkyl, lower alkoxy, Lt; RTI ID = 0.0 > R, < / RTI > The aryl radical is preferably a monocyclic containing 6 to 10 carbon atoms. Preferred aryl groups are those substituted by 1 to 5 substituents independently selected from halogen, nitro, amino, azido, C1-6- alkoxy, C1-6- alkylthio, C1-6- alkyl, C1-6- Each optionally substituted phenyl and naphthyl.
[33] The term " halogen " as used herein includes atoms of Cl, Br, F, I.
[34] The term " hydroxy ", as used herein, is a group of the formula -OH.
[35] The term " thiol " as used herein is a group of the formula -SH.
[36] The term " cyano " as used herein is a group of the formula -CN.
[37] The term " nitro " as used herein is a group of the formula -NO ₂ .
[38] As used herein, the term "nitro oxy" is a group of the formula -ONO _2.
[39] The term " amino ", as used herein, is a group of the formula -NH ₂ .
[40] The term " azido " as used herein is a group of the formula -N ₃ .
[41] The term " carboxy " as used herein is a group of the formula -COOH.
[42] The term " sulfonic acid " as used herein is a group of the formula -SO ₃ H.
[43] As used herein, the term "sulfonamide" is a group of the formula -SO ₂ NH _2.
[44] The term " ester ", as used herein, is a group of the formula -COO-R ¹¹ , wherein R ¹¹ is as defined above except for an oxy derivative, thio derivative or amino derivative.
[45] As used herein, the term "ether" includes groups selected from C1-50-linear or branched alkyl interrupted by one or more oxygen atoms, or a C2-50-linear or branched alkenyl or alkynyl group, or combinations thereof As well.
[46] The term " amido ", as used herein, can be defined as comprising a group of the formula -CONH ₂ , -CONHR ¹¹ or -CONR ¹¹ R ¹² , wherein R ¹¹ and R ¹² are as defined above .
[47] As used herein, the term " heterocycle " refers to a heterocyclic ring having one or more O, S and / or N that interfere with the carbocyclic ring structure, and optionally one carbon of the carbocyclic ring structure may be replaced by a carbonyl , An aromatic nonaromatic cyclic alkyl, alkenyl or alkynyl moiety as defined above. Non-limiting examples of aromatic heterocycles include, but are not limited to, an alkyl group or a pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, Wherein R is selected from the group consisting of pyridyl, quinazolinyl, quinolizinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, indolizinyl, Thiazolyl, thieno (2,3-b) furanyl, furopyranyl, benzofuranyl, benzoxephenyl, isoxazole, Wherein the phenyl ring is optionally substituted with one or more substituents selected from the group consisting of pyridyl, pyrimidinyl, morpholinyl, morpholinyl, morpholinyl, morpholinyl, morpholinyl, morpholinyl, morpholinyl, Alkynyl, isochromanyl, indolinyl, xanthanyl, heptachanthinyl, pteridinyl, 5-aza- Imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. The term " heteroaryl " Non-limiting examples of non-aromatic heterocycles include tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidyl, piperazinyl, imidazolidinyl, morpholino, morpholinyl, 1- oxaspiro (For example, glucose, pentose, hexose, ribose, fructose, which may be substituted) or a lower alkyl or alkyl group, ≪ / RTI > and other alkyls as defined, including, but not limited to, one or more moieties. The term " heterocycle " also refers to a heterocyclic ring having one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or other monocyclic heterocyclic ring Fused or monocyclic heterocyclic group is an alkylene group such as quinuclidinyl, 7-azabicyclo (2.2.1) heptanyl, 7-oxabicyclo (2.2.1) heptanyl, 8-azabicyclo Bicyclic, tricyclic and tetracyclic, spiro groups which are bridged by alkylene groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl,
[48] In the above definitions, substituents such as R ² , R ³ , R ⁴ , R ^2a , R ^3a , R ^4a , R ⁵ , R ⁶ , R ⁷ and R ⁸ are attached to other parts of the molecule by a heteroatom or carbonyl When branched, the linear- or branched-chain, C1-12-, preferably C1-4-alkylene or C2-12, preferably C2-4-alkenylene or -alkynylene bridges, Lt; / RTI > may be inserted between the atom or carbonyl and a point attached to another part of the molecule.
[49] Preferred examples of X are -COOR ⁷ or -CONR ⁵ R ⁶ , wherein R ⁵ , R ⁶ and R ⁷ are preferably hydrogen, C 1-4 -alkyl, phenyl or alkylphenyl.
[50] Preferably, X is carboxy or -CONR ⁵ R ⁶ , wherein R ⁵ and R ⁶ are preferably hydrogen, C 1-4 -alkyl, phenyl or alkylphenyl, especially -CONH ₂ .
[51] Preferably, A ¹ and A ² are each oxygen.
[52] Preferably, R < ¹ > is hydrogen, alkyl, especially C1-12 alkyl, especially lower alkyl or aryl, especially phenyl.
[53] Examples of preferred R ¹ groups include methyl, ethyl, propyl, isopropyl, butyl, iso-or tert-butyl, 2,2,2-trimethyl ethyl, or one or more halogen atoms thereof optionally attached via methylene bridges, Such as trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2 , 2-trichloroethyl.
[54] R ¹ as ethyl is particularly preferred.
[55] Preferably, R ² and R ^2a are independently hydrogen, halogen or alkyl, especially lower alkyl.
[56] Examples of preferred R < ² > and R < ^2a > groups are independently hydrogen, halogen, or a group selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, iso- or tert- Such as trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl- 2,2-trichloroethyl.
[57] In particular, at least one, most preferably both, of R < ² > and R < ^2a >
[58] Preferably, R ^3a , R ⁴ and R ^4a are independently hydrogen, alkyl, especially methyl, ethyl or aryl, especially phenyl or aralkyl, especially benzyl.
[59] Examples of preferred R ^3a , R ⁴ and R ^4a groups are independently selected from the group consisting of hydrogen, halogen, or methyl, ethyl, propyl, isopropyl, butyl, iso- or tert- Halogen atoms such as trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1, -dimethyl-2,2-dibromoethyl, 1,1- Dimethyl-2,2,2-trichloroethyl.
[60] In particular, at least one of R < ⁴ > and R < ^4a >, most preferably both, is hydrogen.
[61] R < ^3a > is especially hydrogen or alkyl, especially lower alkyl, most preferably hydrogen.
[62] Preferably, R < ³ > is hydrogen; Each of which is optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy and which is either directly or by thio, sulfinyl, sulfonyl, carbonyl or oxycarbonyl groups, Alkylene bridges, in particular C1-6-alkyl, especially C1-6-alkyl, which is bonded to the ring via methylene; C2-6-alkenyl or -alkynyl, in particular C2-3-alkenyl or -alkynyl, each optionally substituted by one or more halogens; Azido; Cyanoamido; Carboxy; Each of which is optionally substituted by one or more substituents each independently selected from halogen, C 1-6 -alkyl and phenyl, and which is bonded to the ring directly or via a carbonyl group or a C 1-4 -alkylene bridging, in particular methylene, Pyrrolidinyl, pyridyl, 1-oxydopyridyl, thiomorpholinyl, benzodioxolyl, furyl, oxazolyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl or piperazinyl; Naphthyl; Each of which is optionally substituted by one or more substituents each independently selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl, C 1-6 -alkoxy, C 1-6 -alkylthio, amino, azido, phenyl and nitro, Phenyl or phenylalkenyl bonded to the ring via an oxy, sulfonyl, sulfonyloxy, carbonyl or carbonyloxy group and optionally further C 1-4 -alkylene bridges, especially methylene.
[63] Also preferably, R ³ is C 1-6 -alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato, azido, alkoxy, alkylthio, phenylsulfonyl; Nitrooxy; C2-3-alkenyl or -alkynyl, each of which is optionally substituted by one or more halogens or acetyl; Tetrazolyl, pyridyl, furyl, pyrrolyl, thiazolyl or thienyl; Each of which is optionally substituted by one or more substituents each independently selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl, C 1-6 -alkoxy, amino, azido, phenyl and nitro, , Further C1-4-alkylene bridges, in particular phenyl or phenylalkyl bonded to the bridge through methylene.
[64] Other examples of preferred R ³ groups are hydrogen, halogen or methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethyl or those substituted by one or more halogen atoms, Trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, and 1,1-dimethyl-2,2,2-trichloroethyl.
[65] R ³ is especially C 1-4 -alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato or azido; C2-5-alkenyl or -alkynyl, each optionally substituted by one or more halogens; Thienyl; Or phenyl optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl or azido.
[66] Further examples of preferred R < ³ > groups are C1-6 alkyl and C2-6 haloalkenyl.
[67] Preferably, R ⁵ and R ⁶ are independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl, especially hydrogen or methyl.
[68] In particular, one or more, most preferably both, of R < ⁵ > and R < ⁶ >
[69] Preferably, R ⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl, methoxy, ethoxy, phenyl, Such as, for example, trifluoromethyl, chlorophenyl.
[70] Preferably, R ⁷ is hydrogen, methyl or ethyl, especially hydrogen.
[71] Preferably, R ⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl, phenyl, benzyl or by one or more halogen atoms thereof Such as, for example, trifluoromethyl, chlorobenzyl.
[72] Preferably, R < ⁸ > is hydrogen or methyl.
[73] The combination of one or more such preferred compound groups is particularly preferred.
[74] A particular group of compounds of Formula I (Compound 1A)
[75] A ² is oxygen;
[76] X is ^{-CONR 5 R 6, -COOR 7,} -CO-R 8 or CN, and;
[77] R ¹ is hydrogen or alkyl, aryl, halogen, hydroxy, amino, nitro, cyano;
[78] R ² , R ³ and R ⁴ are the same or different and each independently represents hydrogen or a substituent selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, acyl, acyloxy, sulfonyl, R ³ may additionally be substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, oxy ester, oxyamido, aryl, oxy derivative, heterocycle, vinyl, C2-5 alkenyl, C2-5 alkynyl or azido optionally substituted by halogen, cyano, thiocyano, azido, cyclopropyl, acyl and / or phenyl, or wherein the phenyl moiety is optionally substituted with one or more halogens, alkyl , Phenyl which may be substituted by halogen, haloalkyl, alkoxy, nitro, amino and / or phenyl, most preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, It includes water.
[79] R ^2a , R ^3a and R ^4a are hydrogen;
[80] R ⁵ , R ⁶ and R ⁷ are the same or different and each is independently hydrogen, hydroxy, alkyl, aryl, heterocycle or oxy derivative;
[81] R ⁸ is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, heterocycle, alkylthio or thio derivative.
[82] In such compound 1A, R ¹ is preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl, most preferably methyl, ethyl or n-propyl.
[83] R ² and R ⁴ are preferably independently hydrogen or halogen or methyl, ethyl, propyl, isopropyl, butyl, isobutyl, most preferably each of these is hydrogen.
[84] R ³ is preferably C1-5 alkyl optionally substituted by one or more halogen, cyano, thiocyano, azido, alkylthio, cyclopropyl, acyl and / or phenyl, C2-5 alkenyl, C2-5 alkynyl, cyclopropyl, azido; Phenyl; Phenylsulfonyl; Phenylsulfonyloxy, tetrazole, thiazole, thienyl, furyl, pyrrole, pyridine, wherein the phenyl moiety may be substituted by one or more halogen, alkyl, haloalkyl, alkoxy, or nitroamino; Most preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl.
[85] X is preferably, -COOH, -COOMe, -COOEt, or a -CONH _2, and most preferably, -CONH _2.
[86] A further particular group of compounds of formula I (compound 1B)
[87] X is -CA ¹ NH ₂ , -CA ¹ NHCH ₃ or -CA ¹ N (CH ₃ ) ₂ ;
[88] R < ¹ > is alkyl or phenyl;
[89] R ³ is alkyl, alkenyl, alkynyl, cyano, isothiocyanato, ether, carboxyl, amido, aryl, heterocycle;
[90] R ³ is CH ₂ R ¹⁰ wherein R ¹⁰ is hydrogen, cycloalkyl, oxyester, oxyalkylsulfonyl, oxyarylsulfonyl, aminoalkylsulfonyl, aminoarylsulfonyl, nitrooxy, cyano, isothiocyanate Alkylthio, alkylsulfinyl, alkylsulfonyl, heterocycle, aryloxy, alkoxy or trifluoroethyl; R < 2 >
[91] R ^3a is hydrogen, alkyl or aryl (especially if R ^3a is hydrogen, R ³ is not methyl)
[92] R ³ R ^3a forms a cycloalkyl,
[93] R ² , R ^2a , R ⁴ and R ^4a are each hydrogen.
[94] In the compounds of formula I,
[95] R < ¹ > is preferably alkyl, especially C1-12, more particularly C1-6 alkyl, most preferably ethyl;
[96] R ² , R ^2a , R ^3a and R ^4a are preferably hydrogen;
[97] R ³ is preferably hydrogen; C1-12 alkyl, especially C1-6 alkyl each of which is optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy and which is optionally substituted by one or more substituents selected from the group consisting of thio, , Via a carbonyl or oxycarbonyl group, optionally additionally bonded to the ring via a C 1-4 -alkylene bridging, especially methylene); C2-6-alkenyl or -alkynyl, especially C2-3-alkenyl or -alkynyl, each of which is optionally substituted by one or more halogens; Azido; Cyano; Amido; Carboxy; Thiazolyl, thiazolyl, tetrazolyl, pyrrolidinyl, pyridyl, 1-oxydopyridyl, thiomorpholinyl, benzodioxolyl, furyl, oxazolyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl Or piperazinyl, each of which is optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl and phenyl, and which is either directly or via a carbonyl group or a C 1-4 -alkylene bridging, especially methylene, ); Naphthyl; Is selected from phenyl, phenylalkyl or phenylalkenyl, each of which is optionally substituted by one or more substituents selected from halogen, Ci-6-alkyl, Ci-6 haloalkyl, Ci-6-alkoxy, Ci_6-alkylthio, amino, Optionally substituted by one or more substituents and either directly or through an oxy, sulfonyl, sulfonyloxy, carbonyl or carbonyloxy group, optionally further attached via a C 1-4 -alkylene bridging, especially methylene, to the ring) Lt; / RTI >
[98] R < ³ > is preferably hydrogen or C1-4-alkyl;
[99] R ⁴ and R ^4a are preferably independently hydrogen, C ^1-4 -alkyl, phenyl or benzyl.
[100] A further group of compounds of formula I (compound 1C) is that where X is -CONR ⁵ R ⁶ and R ¹ is hydrogen, methyl, ethyl or propyl, the substituents in the pyrrolidine ring may be mono-, -Methyl or mono-ethyl. ≪ / RTI >
[101] A further group of compounds of formula I (compound 1D) is that wherein X is -CONR ⁵ R ⁶ and R ¹ is each independently hydrogen, C ^1-6 -alkyl, C 2-6 -alkenyl, -alkynyl or cycloalkyl , The substituent in the ring includes a compound in the form of a racemate, each of which is unsubstituted other than alkyl, alkenyl or alkynyl.
[102] A further group of compounds of formula I (compound 1E) are the racemates or enantiomerically enriched forms thereof, especially the pure enantiomers
[103] X is -CA ¹ NH _2, and;
[104] R ¹ is H;
[105] R ³ is selected from the group consisting of azidomethyl, iodomethyl, ethyl optionally substituted by 1 to 5 halogen atoms, n-propyl optionally substituted by 1 to 5 halogen atoms, 1 or 2 methyl and / or 1 Vinyl optionally substituted by one to three halogen atoms, acetylene optionally substituted by C1-4-alkyl, phenyl or halogen;
[106] R < ^3a > is hydrogen or halogen, preferably fluorine;
[107] R ² , R ^2a , R ⁴ and R ^4a are each hydrogen.
[108] A further group of compounds of formula I (compound 1F) are the racemates or enantiomerically enriched forms thereof, especially the pure enantiomers
[109] X is -CA ¹ NH _2, and;
[110] R ¹ is H;
[111] R ³ is azido, oxinitro, C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl optionally substituted by one to six halogen atoms;
[112] R < ^3a > is hydrogen or halogen, preferably fluorine;
[113] R ² , R ^2a , R ⁴ and R ^4a are each hydrogen.
[114] Within all of the above-mentioned ranges, when the carbon atom to which R < ^{1 >} is bonded is asymmetric, it is preferably present as an "S" -structure.
[115] &Quot; Pharmaceutically acceptable salts " according to the present invention include the therapeutically active, non-toxic base and acid salt forms that the compounds of formula (I) can form.
[116] The form of the addition salt with an acid of the formula (I) occurring in free form as a base can be prepared by reacting a free base with a suitable acid such as an inorganic acid such as a hydrohalic acid such as hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; Or organic acids such as hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, Cyclic amic acid, salicylic acid, p-amino salicylic acid, pamoic acid and the like.
[117] The compound of formula (I) containing an acid can be converted into an additional salt form, for example a metal or amine salt, with a therapeutically active, non-toxic base, by treatment with suitable organic and inorganic bases. Suitable base salt forms include, for example, ammonium salts, alkali and alkaline earth metal salts such as salts with organic bases such as lithium, sodium, potassium, magnesium, calcium salts, such as N-methyl-D -Glucamine, hydrabamine salts, and salts with amino acids such as arginine, lysine, and the like.
[118] Conversely, the salt can be converted into the free form by treatment with a suitable base or acid.
[119] The compounds of formula I and their salts, which are included within the scope of the present invention, may be in the form of a solvent. Such solvates include, for example, hydrates, alcoholates and the like.
[120] Many of the compounds of Formula I and some of their intermediates have one or more stereogenic centers in their structures. These stereocenters may exist in the R or S structure, and such R and S rotations are used in accordance with the rules described in Pure Appl. Chem., 45 (1976) 11-30.
[121] The present invention also relates to all stereoisomers, such as enantiomeric and diastereoisomeric forms of the compounds of formula (I), or mixtures thereof, including all possible mixtures of stereoisomers.
[122] In addition, certain compounds of formula I containing an alkenyl group may exist as Z (zusammen) or E (entgegen) isomers. In each case, the invention encompasses a mixture of both and each separated isomer.
[123] Multiple substituents in the pyrrolidone ring may also be in cis or trans relationship to one another with respect to the pyrrolidone ring plane.
[124] Some of the compounds of formula I are also present in tautomeric form. This form, though not precisely indicated in the above formula, is considered to be included within the scope of the present invention.
[125] In the present invention, reference to a compound or compounds is intended to include compounds in their respective possible isomeric forms and mixtures thereof, unless specific isomeric forms are specifically mentioned.
[126] The present invention also encompasses the prodrug forms of the compounds of formula I and the various sub-ranges and sub-groups thereof, within the scope of the present invention.
[127] The term " prodrug " as used herein includes, for example, a form of a compound that is rapidly modified in vivo by the parent compound according to the present invention by hydrolysis in blood. Prodrugs are compounds that contain a group that is removed by biological modification before exhibiting their pharmacological activity. These groups include fragments that are rapidly cleaved in vivo from the compounds containing them, and these compounds maintain or become pharmacologically active after cleavage. The metabolically cleavable group forms a group of well known groups to those skilled in the art. These include, but are not limited to, alkanoyl (i.e., acetyl, propionyl, butyryl, etc.), unsubstituted and substituted carbocyclic aroyl (e.g., benzoyl, substituted benzoyl and 1- and 2-naphthoyl), alkoxycarbonyl , Ethoxycarbonyl), trialkylsilyl (e.g., trimethyl- and triethylsilyl), dicarboxylic acid and formate monoester (e.g., succinyl), phosphate, sulfate, sulfonate, sulfonyl, sulfinyl But are not limited thereto. Compounds containing a metabolically cleavable group are advantageous in that they can exhibit enhanced bioavailability due to the uptake and / or increased solubility of the parent compound by the metabolically cleavable group. [T. Higuchi and V.Stella, " Pro-drugs as Novel Delivery System ", Vol.14 of the A.C.S. Symposium Series; Bioreversible Carriers in Drug Design, ed. Edward B. Roche, Amercian Pharmaceutical Association and Pergamon Press, 1987.].
[128] The compounds of formula (I) according to these inventions may be similarly prepared according to conventional methods as understood by those skilled in the art of synthetic organic chemistry.
[129] The following steps are characteristic synthesis routes for explanation. Other alternative and / or similar methods will be readily apparent to those skilled in the art. With regard to the abbreviations herein, "=" is "is" and "≠" means "other than".
[130] A. cyclization of amino esters
[131] When A ² = O in formula (I), the amino ester of formula AA-II is cyclized, wherein Q ¹ is a leaving group with the oxygen atom to which Q ¹ is attached, in particular Q ¹ is an alkyl group, Is a linear or branched alkyl group having 4 carbon atoms.
[132]
[133] Q ¹ = methyl or ethyl. The reaction is generally known and is generally carried out in the presence or absence of a catalyst such as acetic acid, hydroxybenzotriazole or 2-hydroxypyridine at room temperature to 150 < 0 > C.
[134] Q < ¹ > not methyl or ethyl. The esters of formula AA-II are hydrolyzed under acidic or basic conditions and cyclized under conventional peptide synthesis conditions using a coupling agent, for example, dicyclohexylcarbodiimide (Bondanszky, M., Bondanszky, A. , " The Practice of Peptide Synthesis ", Springer Verlag, 1984).
[135] A.1. Synthesis of AA-Ⅱ by Addition of Itaconate Derivatives
[136] Compounds of formula (AA-II) wherein R ^2a = R ^3a = H and R ³ = COOQ ² , wherein Q ² is an optionally optically active linear or branched alkyl group, may be prepared by reacting a compound of formula AA- Lt; RTI ID = 0.0 > IV < / RTI > according to the following formula:
[137]
[138] Such a reaction can be carried out in a variety of ways as described in [Street, LJ, Baker, R., Book, T., Kneen, CO, ManLeod, AM, Merchant, KJ, Showell, GA, Saunders, J., Herbert, RH, Freedman, EA, J. Med. Chem. (1990), 33, 2690-2697.
[139] A.2. AA-II synthesis by reductive amination
[140] The compound of formula AA-II may be prepared by reductive amination of a compound of formula AA-V with a compound of formula AA-III according to the formula:
[141]
[142] The reaction can be carried out using the conditions described in the literature [Abdel-Magid, AF, Harris, BD, Maryanoff, CA, Synlett (1994), 81-83]. Alternatively, when X is CONR ⁵ R ⁶ , the amine AA-III may be connected via a amide moiety onto a solid support (e.g., a Rink resin).
[143] Compounds of formula AA-V may be prepared by one of the following schemes:
[144]
[145] A.2.1. Aldehydes of the formula AA-VI may be prepared using the intermediate enamine as described in Whitessell, JK, Whitessell, MA, Synthesis, (1983), 517-536 or by the method of Corey, EJ, Enders, Tetrahedron Lett. (1976), 11-14] and alkylated with an alkyl halogenoacetate of formula AA-VII wherein X < ¹ > is a halogen atom and is ozonolyzed.
[146] A.2.2. The nitroester of formula AA-VIII can be converted to a compound of formula AA-V by treating the conjugate base thereof with sulfuric acid in methanol and hydrolysis with an intermediate dimethylacetal (Nef reaction as in Urpi, F., Vilarrasa, J., Tetrahedron Lett. (1990), 31, 7499-7500). The nitro esters of formula AA-VIII are described in Horni, A., Hubacek, I., Hesse, M., Helv. Chim. Acta (1994), 77, < RTI ID = 0.0 > 579. < / RTI >
[147] A.2.3. Ester AA-Ⅹ is a strong base and alkylated by an allyl halide AA-Ⅸ (X ¹ = halogen atom) in the presence of (e.g., lithium diisopropylamide), literature [Amruta Reddy P., Hsiang BCH, Latifi TN, Hill MW, Woodward KE, Rothman SM, Ferrendelli JA, Covey DF, J. Med. Chem. (1996), 39, 1898-1906].
[148] A.3. Synthesis of AA-II by alkylation of -halogenoester
[149] Compounds of formula (AA-II) wherein X = CONR ⁵ R ⁶ , COOR ⁷ or CN can be prepared by alkylating a -Halogenoester wherein X ² is a halogen atom with an amine AA-III.
[150]
[151] The reaction can be carried out using the conditions described in patent application GB 2225322. The synthesis of ester AA-XI is described in paragraph B.
[152] A.4. Synthesis of AA-II by reductive amination of 5-hydroxylactone derivative
[153] Compounds of formula AA-II wherein X = CONR ⁵ R ⁶ , COOR ⁷ or CN and Q ¹ = H and R ^2a = H can be prepared by reacting a compound of formula XII with an amine of formula AA- Can be manufactured by firing:
[154]
[155] The 5-hydroxylactone of formula AA-XII can be synthesized as described in B.1.
[156] B. Condensation of amines to y-halogeno acid derivatives
[157] Compounds of formula AA-XIII react with amines of formula AA-III, according to the formula, when in formula I, A ² = O, X = CONR ⁷ R ⁸ , COOR ⁷ or CN and R ^2a =
[158]
[159] In this formula,
[160] X ³ is a halogen atom, preferably an iodine or chlorine atom,
[161] X ⁴ is a halogen atom, preferably a chlorine atom.
[162] This reaction can be carried out as described in patent application GB 2225322 A.
[163] The formula according to the halogenating agent, for example, TMSI, SOCl ₂ / ZnCl write necessary (because opening the lactone of formula AA-XⅣ in the presence of _2, according to the following formula The compounds of the AA-XⅢ, it Thereafter, the obtained halo the acid (X ⁴ = OH) can be obtained because writing halogenated):
[164]
[165] The opening of the lactone AA-XIV is described in Mazzini, C., Lebreton, J., Alphand, V., Furstoss, R., Tetrahedron Lett. (1998), 38, 1195-1196 and in Olah, GA, Narang, SC, Gupta, BGB, Malhotra, R., J. Org. Chem. (1979), 44, 1247-1250. Halogenation of the obtained halogeno acid ^{(X 4 = OH) (X} 4 = halogen) or esterification (X ⁴ = OQ ¹⁾ may be carried out under conditions well known to those skilled in the art. The lactone of formula AA-XIV can be prepared by one of the following reactions:
[166] B.1. Hydrogenation or conjugation addition of organic metal acids
[167] The compound of formula AA-XIV wherein R ^2a = R ^4a = H can be prepared by hydrogenation of an α, β-derivative of the formula AA-XV or by coupling of an organometallic derivative of the formula R ³ M wherein M is Li, Na, Mg or Zn I) < / RTI > salt by catalytic addition of a conjugate of formula < RTI ID = 0.0 > AA-XV. ≪ / RTI >
[168]
[169] The reaction is described in Alexakis, A., Berlan, J., Besace, Y., Tetrahedron Lett. (1986), 27-1047-1050; Lipshutz, BH, Ellsworth, EL, Siahaan, T., J. Amer. Chem. Soc. (1989), 111, 1351-1358] or under any of the conditions known to those skilled in the art .
[170] B.2. Reduction of succinate derivatives
[171] In the presence of a borohydride reagent, preferably LiBH ₄ or Ca (BH ₄ ) ₂ , in an alcoholic solvent according to the following formula, when R ² = R ^2a = H in the formula AA-XIV, Reduce XVI:
[172]
[173] In this formula,
[174] Q ³ is a methyl or ethyl group,
[175] G ¹ is O or S,
[176] Q ⁴ is a linear or branched alkyl or hydrogen atom having 1 to 4 carbon atoms,
[177] With the proviso that if G ¹ = S then Q ⁴ = alkyl and G ¹ = O then Q ⁴ = H.
[178] Alkylation of C. lactam derivatives
[179] In formula I, when A ² = 0 and X = COOR ⁷ , the compound of formula AA-XVII is reacted with a compound of formula AA-XVII according to the formula:
[180]
[181] Wherein X ⁵ is a halogen atom and M is an alkali metal.
[182] The reaction can be carried out according to the process described in the patent application GB (case number: 15-09).
[183] Compounds of formula AA-XVII can be prepared according to the methods described in Horni, A., Hubacek, I., Hesse, M., Helv. Chim. Acta (1994), 77, 579].
[184] D. Conversion of ester derivatives
[185] When none of the R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a groups is a carboxyl, ester or sulfonic acid, in the formula (I), A ² ═O and X═CONR ⁵ R ⁶ , The corresponding esters of I are transformed into amines under conventional peptide synthesis conditions or directly by ammonia addition cracking using amines or binders such as alkyl chloroformate or dicyclohexylcarbodiimide:
[186]
[187] Wherein R ⁷ is a hydrogen atom or a linear or branched alkyl group having from 1 to 4 carbon atoms.
[188] E. Reduction of α, β-Unsaturated Lactams
[189] In formula I, when A ² = O and R ^2a = R ^3a = R ^4a = H, the compounds of formula I can be obtained by reduction of the unsaturated lactam AA-XIX:
[190]
[191] The reduction step can be carried out under typical conditions known to those skilled in the art, for example, in the presence of Pd / C or alternatively under hydrogen in the presence of an optically active catalyst. If R ² , R ³ or R ⁴ is susceptible to hydrogenation under low pressure conditions, for example, by using Pd / C as catalyst, the double bond of the olefin mixture may be selectively reduced to NaBH ₄ in the presence of CoCl ₂ .
[192] Compounds AA-XIX can be prepared by one of the following processes:
[193] E.1Alkylation
[194] Compounds of formula (AA-III) are alkylated and cyclized by a compound of formula (AA-XX) wherein Q < ⁵ > is a linear or branched alkyl group of 1 to 4 carbon atoms. The alkylation step may be carried out in the presence or absence of a tertiary amine at 0-50 < 0 > C in an inert solvent, for example tetrahydrofuran, dimethylformamide or dichloromethane. The cyclization reaction occurs naturally or can occur continuously in accordance with the method described in A.
[195] E.2Reductive amination
[196] The compound of formula AA-XXI is reacted with a compound of formula AA-III under reductive amination conditions. The first step of this reaction is an inert solvent, e.g., toluene from 0 to 50 NaBH ₃ CN and in the presence of a reducing agent or an acid, such as under ℃, for example, can be carried out in the presence of acetic acid. The synthesis of compound AA-XXI is described in Bourguignon, JJ et al., J. Med. Chem. (1988), 31, 893-897.
[197] F. Functional group transformation of side chain
[198] F.1Reduction of esters to alcohols
[199] One of the groups R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a is G ² -COOQ, wherein A ² = O, X = CONR ⁵ R ⁶ or COOR ⁷ , R ⁷ is a tertiary alkyl group, ⁶ , G ² is a bond or an alkylene group, and Q ⁶ is a linear or branched alkyl group having 1 to 4 carbon atoms is a group represented by R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a And one is a key synthetic intermediate of the corresponding compound, -G ² -CH ₂ OH. Such modifications can be carried out under conditions known to those skilled in the art.
[200] F.2Activation and oxidation of alcohol
[201] Compounds of formula (I) wherein A < ² > = O and one of the R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a groups is -G ² -CH ₂ OH and G ² is a bond or an alkylene group, ^{2, R 2a, R 3,} R 3a, R 4 and R ^4a one air is a major intermediate for synthesis of corresponding compounds -G _² -CH ² X ⁶ or -G ² -CHO, wherein, X ⁶ is chlorine, A bromine or iodine atom or a group of the formula -O-SO ₂ -Q ⁷ or -OQ ⁸ , wherein Q ⁷ is an alkyl or aryl group and Q ⁸ is an alkyl group. Such modifications may be performed under any conditions known to those skilled in the art.
[202] F.3Nucleophilic substitution of activated alcohols
[203] And ^{A 2 = O, R 2,} R 2a, R 3, R 3a, R 4 and R ^4a is a one-self ^{_{-G 2 -CH 2 X 6, G}} 2 is a bond or an alkylene group, G ² is a bond or a an alkylene group, X ⁶ is a formula -O-SO ₂ group or a chlorine, bromine or iodine, the compounds of the formula I as defined in F.2 a -Q ⁷ is ^{R 2, R 2a, R 3} , R 3a, Wherein one of the R ⁴ and R ^4a groups is -G ² -CH ₂ X ⁷ wherein X ⁷ is an azido, halogen, nitro, amino, amino derivative, thio derivative and heterocycle . Such modifications may be performed under any conditions known to those skilled in the art.
[204] F.4Olefinization of aldehydes
[205] And ^{A 2 = O, X = CONR} 5 R 6, and COOR ⁷ or ^{CN, R 2, R 2a,} R 3, R 3a, R 4 and R ^4a is a one-self -G ² -CHO, G ² is a bond Or an alkylene group is a compound of formula (I) wherein one of R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a is -G ² -Q ⁹ wherein Q ⁹ is an unsubstituted vinyl group, Lt; / RTI > is a primary synthetic intermediate of the corresponding compound which is a mono- or di-substituted vinyl group by an atom or an alkyl group. Such modifications may be performed under any conditions known to those skilled in the art.
[206] Alternatively, the compound-G ² -CN can be obtained by reacting its oxime with SeO ₂ from the corresponding aldehyde (Earl, RA, Vollhardt, KPC, J. Org. Chem. (1984) 49, 4786].
[207] F.5Conversion of Acid Derivatives to Heterocyclo
[208] A²= O, R², R^2a, R³, R^3a, R⁴And R^4aOne is -G²-CN or -G²-COQ¹⁰And G²Is a bond or an alkylene group, Q¹⁰An alkoxy group, an aryloxy group, an amino group, a halogen atom Or an amino derivative, and only -COQ¹⁰RTI ID = 0.0 > R < / RTI > is different from X,², R^2a, R³, R^3a, R⁴And R^4aOne of the days -G²-Q¹¹Lt; RTI ID = 0.0 > Q < / RTI >¹¹(I) hydrochloric acid-G²-CO-aryl / heterocycle and an aryl / heterocyclic organometallic, such as trimethyl-pyridyl-stannane, by palladium-catalyzed coupling between a carbonyl group and a -COCl, or (ii) a heterocycle, (1993), 55, 2262 or in Iroka, N., Hamada, Y., Shiori, T., RS, Guiblin, AR, Hobbs, SC, Metassa, VG, Reeve, AJ, Beer, MS), oxazole (in Street, LJ, Bakr, R., Castro, JL, , Middlemis, DN, Noble, AJ, Stanton, JA, Scholey, K., Hargreaves, RJ, J. Med. Chem. (1993), 36, 1529), oxathiazole (Ainsworth, (Goerlitzer, K., Kogt, R., Arch. Pharm. (1990), 323, 847) or thiadiazole (Lamattina, JL , Mularski, CJ, J. Org. Chem. (1984), 49, 4800).
[209] F.6Synthesis of ketone derivatives
[210] And ^{A 2 = O, R 2,} R 2a, R 3, R 3a, R 4 and R ^4a has one air -G ² -CH = CQ ¹² and Q ¹³ or ^{-G 2 -CQ 13 = CHQ 12,} G 2 Is a bond or an alkylene group, Q ¹² and Q ¹³ are each a hydrogen atom or an alkyl group, and the remaining R ¹ , X, R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a are functional groups sensitive to oxidation conditions Wherein one of R ² , R ^2a , R ³ , R ^3a , R ⁴ and R ^4a is -G ² -CO-CHQ ¹² Q ¹³ or -G ² -CHQ ¹³ -CO- Q ¹² is a major synthetic intermediate of the corresponding compound. Such modifications may be performed under any conditions known to those skilled in the art. Such modifications can be carried out in the presence of O ₂ and PdCl ₂ in inert solvents such as dimethylformamide or N-methylpyrrolidine at conditions known to the person skilled in the art, for example at 0 to 50 ° C (Bird , Transition Metals Intermediate in Organic Synthesis , Academic Press, NY, (1967), 88-111).
[211] F.7Induction of ketone
[212] And ^{A 2 = O, X = CONR} 5 and R ⁶ or ^{COOR 7, R 2, R 2a} , R 3, R 3a, R 4 and R ^4a has one air -G ² -CO-Q ¹⁴ (wherein, G ² Is a bond or an alkylene group and Q ¹⁴ is an alkyl group) can be prepared by (i) reduction of the alcohol-G ² -CHOH-Q ¹⁴ (March, J., Advanced Organic Chemistry, Third Edition , John Wiley & Sons, (1985), 809), (ii) Lal, GS, Pez, GP, Pesaresi, RJ, Prozonic, FM, Chem. Commun. (1999), using the conditions described in the 215-216] is a major synthesis intermediates for the fluorinated side chain -G ² Synthesis of -CF ₂ -Q ^14.
[213] F.8Synthesis of Alkynyl Derivatives
[214] And ^{A 2 = O, R 2,} R 2a, R 3, R 3a, R 4 and R ^4a is a one-self ^{-G 2 -C = C (X 8} ), G 2 is a bond or an alkylene group, X ⁸ is a halogen atom, provided that the remaining ^{R 1, X, R 2,} R 2a, R 3, R 3a, R 4 and R ^4a are the compounds of formula I which does not contain sensitive functional groups to the strong base is, R ^2, R ^2a, One of the R ³ , R ^3a , R ⁴ and R ^4a groups is -G ² -C≡CQ ¹⁵ , wherein Q ¹⁵ is a hydrogen, halogen, alkyl or aryl group. This modification can be performed in the following manner.
[215] (See for example Michel, P., Rassat, A., Tetrahedron Lett. (1999), 40, 8579-8581) after base-induced -Termination with a haloacetylene derivative (Q ¹⁵ = halogen) 1 equivalent of t-BuOK at low temperature), metal-catalyzed substitution of halogen by organometallic species (for example CuCN as described in Micouin, L., Knochel, P., Synlett (1997), 327 . ≪ / RTI > by MeZnCl in the presence of LiCl.
[216] Direct conversion to metal acetylenes (e. G., 2 equivalents of n-butyl lithium) and conversion to alkyl halides or carbonyl derivatives (Corey, EJ, Fuchs, PL, Tetrahedron Lett. (1972) -3772). ≪ / RTI >
[217] F.9Synthesis of alkane
[218] And ^{A 2 = O, R 2,} R 2a, R 3, R 3a, R 4 and R ^4a is a lifter and -G ^{2 -C = CQ 16 Q 17,} G 2 is a bond or an alkylene group, Q ¹⁶ and Q ¹⁷ is a compound of formula I, with an alkyl or ^{fluorinated, R 2, R 2a, R} 3, R 3a, R 4 and R ^4a has one air ^{-G 2 -CH-CH-Q 16} Q 17 of the corresponding compounds Lt; / RTI >
[219] The reduction step can be performed with hydrogen under conventional conditions known to those skilled in the art, for example, in the presence of Pd / c (March, J., "Advanced Organic Chemistry, Third Edition", John Wiley & ), 1101-1102).
[220] F.10Synthesis of (halo) azidoaryl derivatives
[221] A ² = O, X = CONR ⁵ R ⁶ , COOR ⁷ or CN and one of the R ² , R ³ or R ⁴ groups is -G ² -Q ¹⁸ wherein Q ¹⁸ is nitroaryl or triazenauryl, G ² is a bond or an alkylene group. Compounds of the formula I are those wherein one of the R ² , R ³ or R ⁴ groups is GQ ¹⁰ , wherein Q ¹⁹ is one or several halogen atoms, preferably Br or F atoms Lt; / RTI > is a primary synthetic intermediate of the corresponding compound. These modifications include reduction of the nitro or triazine moiety to aniline by means known to those skilled in the art, selective introduction of one or several halogen atoms (Xing-teng, D., Guo-bin, L., Synth. Commun. (1989), 19, 1261) and by the conversion of azines to azides by well-known methods.
[222] F.11Heterocycle synthesis from amines
[223] ^{One of} R ² , R ³ or R ⁴ is -G ²⁰ -Q ²⁰ wherein Q ²⁰ is COOH, CONH ₂ or CN, A ¹ = O, X = CONR ⁵ R ⁶ , COOR ⁷ or CN, compounds of formula I G ² is a bond or an alkylene group) is, R ^2, R ³ or R ⁴ is G ² air one -NH ₂ or G _² -CH ² -NH ₂ in a major synthetic intermediate of the corresponding compound , In which one of the R ² , R ³ or R ⁴ groups is G ² -Het or G ² -CH ₂ -Het wherein Het is a heterocycle linked by a nitrogen atom optionally substituted by one or several halogen atoms Lt; / RTI >
[224] A Curtius rearrangement (when X = CONR ⁵ R ⁶ , CN or COOR ⁷ wherein R is different from H) and R ² , R ³ or R ⁴ is G ² -COOH, For example, the action of diphenylphosphorazidate and triethylamine as described in [Kim, D., Weinreb, SM, J. Org. Chem. (1978), 43, By deprotection of the amine function by hydrogenolysis or by any condition known to those skilled in the art to provide R ² , R ³ or R ⁴ = G ² -NH ₂ , (Jefford, CW, Tang, Q., Zaslona, A., J. Amer. Chem. Soc. (1991), 113, 3513-3518) to provide a heterocycle, and one or several Deformation is effected through selective introduction of halogen atoms.
[225] X is CONR ⁵ R ⁶ , CN or COOR ⁷ and R ² , R ³ or R ⁴ is G ² -CONH ₂ wherein X is different from CONR ⁵ R ⁶ or G ² -CN and is different from CN (Miles, RW, Samano, V., Robins, < / RTI >< RTI ID = 0.0 > , MJ, J. Amer. Chem. Soc. (1995), 117, 5951-5957).
[226] F.12Synthesis of triazole
[227] And A ² = O, R a ^{2, R 2a, R 3,} R 3a, R 4 or R ^4a is a lifter is -G _² -CH ² N ₃ (where, G ² is a bond or alkylene group) The compound of Formula I A compound is a major synthetic intermediate of the corresponding compound wherein one of the R ² , R ^2a , R ³ , R ^3a , R ⁴ or R ^4a groups is G ² -CH ₂ -triazole. This modification can be carried out by prolonged heating in the presence of 1- (triphenylphosphoranylidene) -ketone derivatives (Hammerschmidt, F., Polsterer, JP, Zbiral, E., Synthesis 415]).
[228] F.13decomposition
[229] When the compound of formula I represents one or several stereogenic centers and this non-stereoselective method of synthesis is used, the decomposition of the mixture of stereoisomers is preferably carried out in the reverse or, preferably, , One or several steps, including chromatographic separation, followed by a general sequential separation of the mixture of diastereoisomers into their constituent racemates, most preferably in the reverse or, preferably, in the forward mode, , It is best to perform each of the racemates with one or more final decomposition steps to their enantiomers using chromatographic separation. Alternatively, if a partial stereoselective synthesis method is used, the final step can be carried out in reverse or preferably using a chromatographic separation, preferably in an achiral or chiral phase, in a forward mode, separating the diastereomer .
[230] The particular intermediate compounds described above, especially the compounds of formula (AA-II) in which the various substituents have the meanings given above, are novel and are also part of the present invention. Where the leaving group is pharmaceutically acceptable, these novel intermediates have the same usefulness as described for the compounds of formula I below.
[231] It has been found that the compounds of formula I and their pharmaceutically acceptable salts are useful in a variety of pharmaceutical indications.
[232] For example, the compounds according to the present invention are useful for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.
[233] These compounds may also be used in the treatment of bipolar disorder, manic, depression, anxiety, migraine, tricuspid or other neuralgia, chronic pain, neuropathic pain, cerebral vasculopathy, cardiac arrhythmia, myalgia, cocaine abuse, stroke, And other movement disorders, neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, rigidity, Parkinson's disease and other degenerative diseases.
[234] The compounds according to the invention are also useful for the treatment of bronchial asthma, asthma and allergic bronchitis, asthma syndrome, bronchial hyperresponsiveness, bronchospastic syndromes and allergic and vasomotor rhinitis and rhinoconjunctivitis. .
[235] Accordingly, in a further aspect, the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of the aforementioned neurological and other diseases.
[236] In particular, the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of epilepsy, bipolar disorder, chronic pain or neuropathic pain, migraine, bronchial, asthma or allergic diseases will be.
[237] The activity and properties of the active compound, in vitro or in vivo oral efficacy and stability may vary significantly depending on the optical isomer of the compound described.
[238] In a preferred embodiment, the active compound is administered in the enantiomerically loaded form, i.e. in the form of virtually one isomer.
[239] For example, in the case of a compound of formula (I) wherein R ¹ is ethyl, X is -CONH ₂ and A ² is oxygen, if R ³ is propyl and all remaining substituents are hydrogen, preferably S Amide), R (ring) enantiomer, R ³ is 2,2-difluorovinyl, and all remaining substituents are hydrogen, preferably S (butanamide), S (ring) enantiomer.
[240] The present invention also relates to a pharmaceutical composition comprising one or more compounds of formula I or a pharmaceutically acceptable salt thereof, in a mammal in need thereof for the treatment of epilepsy, migraine, bipolar disorder, chronic pain or neuropathic pain, or bronchial, asthmatic or allergic diseases ≪ / RTI > comprising administering a therapeutically effective amount of a compound of formula
[241] The method of the present invention includes administering to a mammal (preferably a human) suffering from the above-mentioned disease or condition a compound according to the present invention in an amount sufficient to alleviate or prevent the disease or disorder.
[242] Compounds containing, but not limited to, compounds containing from 5 to 1000 mg, preferably from 25 to 500 mg, of the active ingredient per unit dose are suitably administered in suitable doses.
[243] The term " treatment " as used herein includes healing and prophylactic treatment.
[244] &Quot; Healing " means efficacy in the treatment of the current condition of the disease or disease.
[245] &Quot; Preventive " means preventing the occurrence or recurrence of a disease or disease.
[246] The term " epilepsy " as used herein refers to a brain dysfunction characterized by the occurrence of periodic, unpredictable seizures. Seizures may be " non-interstitial " when occurring in the brain of the settled brain by treatment such as electrical shock or chemical seizures, and may be " interstitial " if occurring without obvious stimuli.
[247] As used herein, the term " seizure " refers to a transient change in behavior due to a discrete, synchronous and periodic firing of the neuronal cell population.
[248] The term " migraine " as used herein means a disorder characterized by recurrent occurrence of headache of varying degrees, frequency and duration. Generation usually occurs only in one side, and generally involves anorexia, nausea, vomiting, phobias and / or photoreactivation. In some cases, they are preceded by neurological and emotional disorders. The migraine can last from 4 hours to about 72 hours. The International Headache Society (IHS, 1988) classifies headache as a major type of migraine with aura (classic migraine) and migraine without aura (common migraine). A migraine with a history of headache consists of a unique visual, sensory, horses, or somatic symptoms. Headache without these symptoms is called migraine without aura.
[249] The term " bipolar disorder " as used herein means a disorder classified as a mood disorder according to the Diagnostic and Statistical Manual of Mental disorders of the fourth edition (Diagnostic and Statistical Manual of Mental Disorders DSM-IV TM), American Psychiatry Association, Washington, DC, 1994). Bipolar disorder is generally characterized as a condition in which the patient's hyperactivity, activity, and mood are significantly inhibited, and such inhibition is associated with increased mood and increased energy and duration of action (manic or hypomanic) or mood reduction, Depression) that occur spontaneously and occur repeatedly (i.e., two or more times). Bipolar disorder is classified into four major categories in DSM-IV (bipolar I disease, bipolar II disease, circulatory matrix and bipolar disorder unless otherwise stated).
[250] As used herein, the term " manic episode " refers to a unique period of abnormal, sustained elevated, hyper-delusional, or delicate mood, with subdued tone and psychomotor excitation symptoms.
[251] As used herein, the term " hypersensitivity " means that the severity is less than the acute manic episodes of polarity.
[252] As used herein, the term " primary depressive episode " refers to a period of more than two weeks in which there is a loss of interest or pleasure or depressed mood in almost all activities exhibiting reduced concentration and psychomotor retardation symptoms.
[253] The term " mixed episode " as used herein means a period of time (more than a week duration) in which the criteria are met for nearly daily major depression episode and manic episode.
[254] As used herein, the term " chronic pain " refers to acute pain and other disease conditions that are increasingly recognized as diseases. Typically, the pain defined as pain that lasts beyond the normal treatment time can also be considered chronic at the moment when the individual perceives that their pain will continue to be part of these lives in the future. Major Chronic Pain New drums can usually contain neural elements that are harder to cure than acute body pain.
[255] As used herein, the term " neuropathic pain " refers to a pain that begins by causing a neurologic change in the nerve signaling a signal of the presence of a toxic stimulus and increasing the temporal sensation of pain when no recognizable stimulus is present it means. That is, it is believed that the pain system can be started and stopped by itself.
[256] The activity of a compound of formula I as an anticonvulsant, or a pharmaceutically acceptable salt thereof, can be measured in a high frequency seizure model. The purpose of this test is to evaluate the potential of the compound as a seizure inhibitor by high frequency seizures induced by acoustically sensitive mice, a genetic animal model causing reflex seizures. In the primary systemic epilepsy model, seizures occur without electrical or chemical stimulation, and at least some of the seizure types are similar to seizures and clinical manifestations that occur in humans (Loescher W. & Schmidt D., Epilepsy Res. (1998) 2, pp. 145-181; Buchhalter JR, Epilepsia (1993), 34, S31-S41). The results obtained with compounds of formula I show strong pharmacological effects.
[257] Another indication assay of potential anticonvulsant activity is binding to the levetiracetam binding site (LBS) as described below.
[258] The activity of a compound of Formula I or a pharmaceutically acceptable salt thereof in chronic neuropathic pain can be measured in an animal model. For example, chronic neuropathic pain can be modeled by pharmacologically inducing diabetes in rats. In this model, the animals exhibit hyperalgesia that is exacerbated by impairment receptive stimuli, ie, symptoms observed in patients with generally painful peripheral neuropathy (Courteix C, Eschalier, A., and Lavarenne J., Pain, 53 1993) 81-88). This model has been shown to have a high pharmacological predictability (Courteix C, Bardin M., Chantelauze C., Lavarenne J and Eschalier, A., Pain, 57 (1994) 153-160).
[259] The activity of a compound of Formula I or a pharmaceutically acceptable salt thereof in bipolar disorder can be evaluated in animal models. For example, bipolar disorder and especially mania can be modeled by pharmacologically inducing fruit behavioral disturbances in rats and evaluating their behavior in the Y maze. In these situations, effective therapeutic agents in people, such as lithium and sodium interstitial drugs, reduce hyperactivity disorder and confirm the predictability of the model (Cao BJ, and Peng N, A ;, Eur. (1993) 177-181, Vale AL and Ratcliffe F. Psychopharmacology, 91 (1987) 352-355).
[260] Potential anti-asthmatic properties of a compound of formula I or a pharmaceutically acceptable salt thereof were tested in an allergic asthmatic animal model, wherein guinea pigs sensitive to orbuumin were stimulated with antigen and pulmonary function and changes in airway inflammatory cell capacity (Yamada et al. (1992) Development of an animal model of late asthmatic response in guinea pigs and anti-asthmatic drugs Prostaglandins, 43 : 507-521).
[261] The activity in the above-mentioned indications can, of course, be measured by carrying out appropriate clinical trials in a manner known to the person skilled in the art, generally in the design of clinical trials and / or in certain indications.
[262] In the treatment of the diseases, the compounds of formula I and the pharmaceutically acceptable salts can be used in effective daily doses and can be administered in the form of pharmaceutical compositions.
[263] Therefore, another embodiment of the present invention relates to a pharmaceutical composition comprising an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
[264] In order to prepare a pharmaceutical composition according to the present invention, one or more compounds of formula I, or a pharmaceutically acceptable salt thereof, are well mixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to those skilled in the art.
[265] Suitable diluents and carriers may take a wide variety of forms depending on the desired route of administration, for example, oral, rectal or parenteral administration.
[266] The pharmaceutical compositions comprising the compounds according to the invention can be administered, for example, orally or parenterally, that is intravenously, intramuscularly or subcutaneously, intrathecally.
[267] Pharmaceutical compositions suitable for oral administration may be solid or liquid and may take such forms as, for example, tablets, pills, dragees, gelatin capsules, solutions, syrups and the like.
[268] For this purpose, the active ingredient may be mixed with an inert diluent such as starch or lactose or with a non-toxic pharmaceutically acceptable carrier. Alternatively, such pharmaceutical compositions may also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatin, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon Dextrates, sweeteners such as sucrose or saccharin, or dyes or flavoring agents such as peppermint or methyl salicylate.
[269] The present invention also contemplates compositions that are capable of releasing the active substance in a controlled manner. Pharmaceutical compositions that can be used for parenteral administration are in the conventional form, for example, in the form of an aqueous or oil solution or suspension, usually contained in ampoules, disposable syringes, glass or plastic bottles or injection containers.
[270] In addition to the active ingredient, such solutions or suspensions may also contain sterile diluents such as water for injection, physiological saline, oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, For example, ascorbic acid or sodium bisulfite, a chelating agent such as ethylenediamine-tetra-acetic acid, a buffer such as acetate, citrate or phosphate, and a medicament for controlling the osmolal concentration, such as sodium chloride or dextrose, ≪ / RTI >
[271] Such pharmaceutical forms are prepared using methods commonly used by pharmaceutical companies.
[272] The amount of active ingredient in the pharmaceutical composition is within a wide concentration range and depends on various factors such as the sex, age, weight and severity of the patient, and the method of administration. Accordingly, the amount of the compound of the formula (I) in the composition for oral administration is at least 0.5% by weight based on the total weight of the composition, and can be up to 80%.
[273] In the present invention, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered alone or in combination with other pharmaceutically active ingredients. Non-limiting examples of such additional compounds that may be mentioned for use with the compounds according to the invention include antiviral agents, anticonvulsants (for example, baclofen), anti-vomiting agents, vomiting symptom stabilizers, (I. E., Mianserin, fluoxetine, < / RTI > eicosapentaenoic acid), anesthetics, analgesics (e.g., aspirin, ibuprofen, parahematol), narcotic analgesics, local anesthetics, opioid analgesics, lithium salts, , Tramadol), tricyclic antidepressants (e.g., imipramine, desipramine), anticonvulsants (e.g. valproic acid, carbamazepine, phenytoin) (Eg, chlopromazine), calcium ion channel blockers, amphetamines, antidepressants, antidepressants, antidepressants, antidepressants, antipsychotics (eg, risperidone, haloperidol), neuroleptics, benzodiazepines (eg, diazepam, clonazepam), phenothiazine Clonidine, lidocaine, meg Teal, the capsaicin, caffeine, quetiapine, serotonin antago Nice, β- blockers, antiarrhythmics, triptans, Ergo agent derivative.
[274] Of particular interest in the present invention is the combination of one or more compounds of formula I or a pharmaceutically acceptable salt thereof with one or more compounds which induce nerve inhibition mediated by GABA _A receptors. The compounds of formula I increase the efficacy of compounds that induce neurotoxicity, which is regulated by GABA _A receptors, which can effectively treat diseases and diseases in many cases under reduced side effects.
[275] Examples of compounds that induce neural inhibition mediated by GABA _A receptors include the following compounds: benzodiazepines, barbiturates, steroids and anticonvulsants such as valproate, vialogavitrin, thiabbin, or their pharmaceutical Acceptable salt.
[276] Benzodiazepines include 1,4 benzodiazepines such as diazepam and clonazepam, and 1,5 benzodiazepines such as clobazam. A preferred compound is clonazepam.
[277] Barbiturates include phenobarbital and pentobarbital. A preferred compound is phenobarbital.
[278] Steroids include adrenocorticotropic hormones such as tetracosaccharide acetate and the like.
[279] The anticonvulsant may be selected from the group consisting of hydantoin (phenytoin, etotone and the like), oxazolidine (trimethadione, etc.), succinimide (etoschiimide and the like), penameride (penameride, acetylpenetouride, (Such as gamma-amino-beta-hydroxybutyric acid), sodium valproate and derivatives, carbamazepine, and the like.
[280] Preferred compounds include valproic acid, valproic acid, valproate, pivoxil, sodium valproate, semi-sodium valproate, divalproex, clonazepam, phenobarbital, do.
[281] In a preferred oral composition, the daily dose is from 5 to 1000 mg of the compound of formula (I).
[282] In the composition for parenteral administration, the amount of the compound of the formula (I) is 0.5% by weight or more, and may be up to 33% by weight based on the total weight of the composition. In a preferred parenteral composition, the dosage unit is from 5 mg to 1000 mg of the compound of formula (I).
[283] The daily dose is within a large dosage unit of the compound of formula I, and is generally from 5 to 1000 mg. It should be understood, however, that the particular dose may be appropriate in certain cases depending on the individual requirements after the judgment of the therapist.
[284] The amount of active ingredient (a compound that induces nerve suppression regulated by Compound I and GABA _A receptor) in the pharmaceutical composition of the present invention varies greatly depending on the composition to be administered to the mammal, the disease to be treated, other existing components, and the like . In general, the amount of the compound that induces neural inhibition, as regulated by the GABA _A receptor, and the amount of Compound I, relative to the provided composition, and the dosage form can be readily determined by routine procedures.
[285] The following examples are not intended to limit the invention in any way, but merely provided for illustrative purposes. Those skilled in the art will recognize that routine modifications and adaptations of the following examples are possible without departing from the spirit or scope of the invention.
[286] Unless otherwise stated in the following examples, characterization of the compound is carried out according to the following method:
[287] NMR spectra were acquired using a BRUKER AC 250 Fourier Transform NMR Spectrometer (available from Aspect 3000 computer) and a Bruker AC 250 Fourier Transform NMR Spectrometer equipped with a 5 mm ¹ H / ¹³ C dual probehead. ) or eseuji Indigo ² computer (SG Indigo ² computer) and 5mm in the reverse geometry ^{(inverse geometry) 1 H / 13} C / 15 N triple probe head (triple probehead) a Bruker Diallo x 400 FM NMR (BRUKER DRX 400 provided with a FT NMR). Compounds are studied in DMSO-d ₆ (or CDCl ₃ ) solutions at a probe temperature of 313 K and a concentration of 20 mg / ml. The device is immobilized on the deuterium signal of DMSO-d ₆ (or CDCl ₃ ). Chemical shifts are provided in the ppm down field from the TMS taken as the internal standard.
[288] Mass spectrometer measurements in LC / MS mode are performed as follows:
[289] HPLC conditions
[290] The analysis is carried out using a WATERS Alliance HPLC system equipped with INERTSIL ODS 3, DP 5 μm, 250 X 4.6 mm column.
[291] The gradient was 100% Solvent A (acetonitrile, water TFA (10.90 / 0.1), v / v / v) to 100% solvent B (acetonitrile, water, TFA 90 / 10/0.1), v / v / v). The flow rate was set at 2.5 ml / min, and a 1/10 spilllet was used just prior to the API source. Chromatography is performed at 30 < 0 > C.
[292] MS condition
[293] Samples were dissolved in 70/30 acetonitrile / water at a concentration of about 250 μg / ml. API spectra (+ or -) were performed using FINNIGAN (San Jose, Calif., USA) LCQ ion trap mass spectrometer. The APCI source is operated at 450 占 폚, and the capillary heater is operated at 160 占 폚. The ESI source operates at 3.5 kV and the capillary heater operates at 210 캜.
[294] Mass spectrometer measurements in DIP / EI mode are performed as follows: Samples were evaporated by heating the probe to 50 DEG C to 250 DEG C for 5 minutes. EI (Electron Impact) spectra are recorded using a Finnigan (San Jose, Calif., USA) TSQ 700 series tandem quadrupole mass spectrometer. The source temperature is set to 150 占 폚.
[295] The specific rotation is recorded on a Perkin-Elmer MC241 or 341 polarizer. The rotation angle is recorded at 25 ° C in 1% MeOH solution. For some molecules, the solvent is CH ₂ Cl ₂ or DMSO due to solubility problems.
[296] The water content is measured using a Metrohm microcoulometric Karl Fischer titrator with a metro force microlocalmetric Karl Fischer titrator.
[297] The purified chromatographic separation uses a Jobin Yvon-type axial compression column (80 mm inner diameter) modified in-house at a flow rate of 70 to 15 ml / min on a silica gel 60 mulch (Merck) with a particle size of 15-40 쨉 m . The amount of silica gel and solvent mixture is described in each step.
[298] The purified chiral chromatographic separation was carried out in-house with various mixtures of C5 to C8 linear, branched or cyclic alkanes and lower alcohols at DAICEL Chiralpak AD 20 m, 100 * 500 mm column at < RTI ID = 0.0 & Is performed using a build instrument. The solvent mixture is described in each process.
[299] The powder X-ray diffraction pattern was obtained using a monochromator, Cu Kα radiation (40 kV, 35 mA operating tube) and a scintillation counter on a computer-controlled Philips PW 1710 equipped with a PW3710 mpd controller at room temperature and under the atmosphere. The data is collected over an angle of 4 ° to 50 ° 2θ in continuous scan mode using a scan rate of 0.02 2θ / s.
[300] The following abbreviations have been used in the examples:
[301] AcOEt ethyl acetate
[302] AOH acetic acid
[303] BuLin-butyllithium
[304] n-Bu ₃ P tri-n-butylphosphine
[305] ClCOOEt or ClCO2 < / RTI _> Et ethyl chloroformate
[306] DCE1,2-dichloroethane
[307] DIC diisopropylcarbodiimide
[308] DMSO dimethylsulfoxide
[309] DSC Different Scanning Calorimetry
[310] DMFN, N-dimethylformamide
[311] Et ₃ N triethylamine
[312] Et ₂ O diethyl ether
[313] EtOH Ethanol
[314] FMOC fluorenylmethyloxycarbonyl
[315] LDA lithium diisopropylamide
[316] MeCOCl lithium diisopropylamide
[317] MeCN acetonitrile
[318] MeOH Methanol
[319] MTBE methyl tertbutyl ether
[320] NMPN-methylpyrrolidinone
[321] PhMe toluene
[322] PrepLC Purification Liquid Chromatography
[323] i-Pr ₂ O diisopropyl ether
[324] i-PrOH isopropanol
[325] TFA Trifluoroacetic acid
[326] THF tetrahydrofuran
[327] TMOF trimethyl orthoformate
[328] TMSCI Chlorotrimethylsilane
[329] TMSI iodotrimethylsilane
[330] Unless otherwise stated in the examples, the compounds are obtained in the free (non-salt) form.
[331] Example 1. Synthesis of 4-substituted 2-oxo-pyrrolidine butanamide by reductive amination of aldehyde ester
[332] 1.1. Synthesis of 3-substituted-4-oxo-butanoic acid ester
[333] 1.1.1. Route A: alkylation of enamine
[334] The synthesis of 5,5-dimethyl-3-formyl-hexanoic acid methyl ester (361) is representative:
[335]
[336] To a three-necked flask equipped with a Dean-Stark mechanism under argon was added diisobutylamine (4.62 ml from Acros), 4,4-dimethylpentanel 362 (2.5 g, 0.021 mol) in toluene (20 ml) The solution was heated at 130 < 0 > C for 2 hours and water was extracted. The yellow solution was cooled to room temperature and methyl bromoacetate (3.7 g, 0.024 mol) was added in one portion. The pink solution was stirred overnight at room temperature and stirred at 90 < 0 > C for 1 hour. The organic layer was washed with HCl 1 N and a saturated aqueous sodium bicarbonate solution, dried over magnesium sulfate, filtered and evaporated to give a distilled oil under reduced pressure (1 mm Hg) to give methyl 5,5-dimethyl-3-formyl-hexanoate Ester ( 361 ) (1.1 g, 0.05 mol, Teb (1 mm Hg): 69-71 캜). The aldehyde ester was then used in the reductive amination step. Alternatively, alkylation with ethyl bromoacetate can be carried out in the presence of toluene acetonitrile 1/1 (v / v) as solvent. In addition, the final aldehyde can be distilled under reduced pressure.
[337] 1.1.2. Other synthetic routes
[338] Aldehyde esters can also be obtained by other methods including the following methods:
[339] (I) alkylation of the hydrazone of the bromoacetate derivative. For example, the 2,2-dimethyl-ethyl ester of 5- (phenyl) -3-formyl-pentanoic acid can be prepared by reacting N- (4-phenyl) -propylidene-N, N-dimethylhydrazone with tert- Is reacted with moacetate and LDA and is then ozonolyzed with an alkylated hydrazone.
[340] (Ii) the addition of nitromethane to the alpha, beta -unsaturated ester. 3- (3-Bromo-phenyl) -4-oxo-butanoic acid ethyl ester is prepared by reacting the nitromethane with 3- (3-bromo-phenyl) -4-oxo-butanoic acid ethyl ester in the presence of 1.8-diazabicyclo [5.4.0] undec- -Phenyl) -acrylic < / RTI > ethyl ester, obtained by oxidation of the nitro derivative under Nef conditions, and the hydrolysis of the methyl-acetal is controlled by HCl.
[341] (Iii) Ozone decomposition of 4-pentenoic derivatives. 2-Benzyl-4-oxo-butanoic acid ethyl ester is obtained by alkylating 3-phenyl-butanoic acid ethyl ester and allyl bromide with lithium diisopropylamide followed by ozone decomposition and reduction of ozone with PPh ₃ .
[342] 1.2. Reductive amination of 3-substituted-4-oxo-butanoic acid ester and cyclization to pyrrolidin-2-
[343] 1.2.1. Reductive amination
[344] The synthesis of methyl 4 - {[((1S) -1-aminocarbonyl) propyl] amino} butanoate ( 363 )
[345]
[346] In a three-necked flask equipped with a reflux condenser, under argon, MeOH in ah aldehyde (361) (1.7g, 0.09mol) , (S) -2- amino-butane amide (1.58g, 0.15mol), and molecular sieves (Aldrich (Aldrich) was heated at < RTI ID = 0.0 > 60 C < / RTI > for 0.5 h. The suspension was cooled to 0 < 0 > C and sodium bicarbonate (0.55 g) was added in portions. After 1 hour at room temperature, the reaction mixture was diluted with ether, washed with water, dried with magnesium sulfate, filtered and evaporated to give a yellow oil. Methyl 4 - {[((1S) -1-aminocarbonyl) propyl] amino} butanoate ( 363 ) is used directly in the next step without further purification.
[347] Alternatively, the reductive amination can be carried out under the same conditions with other reducing agents such as NaBH ₃ CN or NaBH (OAc) ₃ (using an equivalent amount of 1.4 mol with respect to the aldehyde ester).
[348] 1.2.2. Cyclization of butanoic acid (methyl or ethyl) esters
[349] (2S) -2- (4-neopentyl-2-oxo-1-pyrrolidinyl) butanamide ( 149 and 148 ) are representative:
[350]
[351] In a three-necked flask equipped with a reflux condenser under argon, the oil component 363 was dissolved in a solution of toluene and 1,2-dichloroethane (25 ml each) in the presence of hydroxybenzotriazole (2.05 g, available from Aldrich) / 1 mixture, the solution was heated to 90 < 0 > C for 2 hours and cooled to room temperature. The organic phase was washed with successively saturated aqueous sodium bicarbonate solution and water, dried with magnesium sulfate, filtered and evaporated to give a brown solid (1.8 g) which was purified on silica gel (eluent: CH ₂ Cl ₂ / MeOH 95/05 v / v) as the eluent to give (2S) -2- (4-neopentyl-2-oxo-1-pyrrolidinyl) butanamide (0.89 g, 0.0036 mol). The two isomers were separated by chromatography on a chiral stationary phase (EtOH-hexane 1/1 (v / v)) and two stereoisomers (0.35 g and 0.37 g, respectively) were obtained after recrystallization from toluene. Physicochemical properties are described in the table. Alternatively, the crystallization of the amino ester can be carried out with a reagent other than hydroxy-benzotriazole, such as acetic acid (as a solvent) or 2-hydroxy-pyridine (1 equivalent). When acetic acid is used as a solvent for crystallization, the reaction mixture is evaporated to dryness under vacuum, diluted with dichloromethane and treated as above.
[352] 1.2.3. Other Crystallization
[353] Alternatively, the crystallization can be carried out by two steps: (i) acidic or basic hydrolysis of the ester and (ii) crystallization to the activated ester under the general conditions described in peptide synthesis.
[354] 1.3. High shape synthesis of pyrilidone
[355] 1.3.1. Attachment of FMOC-protected amino acid to link amide resin
[356]
[357] 4 g of linkamide resin (0.51 meq / g, 100-200 mesh) was placed in a glass container and stirred for 30 minutes in 20% v / v piperidine / DMF (40 ml). Water was removed from the resin and the entire deprotection step was repeated. The resin was filtered, washed (6 x DMF) and dried. The resin was suspended in DMF (40 ml), treated with N-Fmoc-2-aminobutyric acid (3.02 g, 9.28 mmol) and 1,3-dicyclohexylcarbodiimide in DMF (20 ml) mmol). < / RTI > The reaction was stirred at room temperature for 1 hour, filtered, washed (DMF) and the coupling process was repeated. The resin was filtered, washed (6 x DMF, 6 x CH ₂ Cl ₂ ), dried and used in the next step.
[358] 1.3.2. Reductive amination and cyclization of the added 5-hydroxy-4-propyl-furan-2-
[359]
[360] 100 mg of N-Fmoc-2-aminobutyramide resin (0.051 mmol) was contained in the molten polypropylene syringe. The Fmoc group was removed using 20% piperidine in DMF. To amino resin was added 5-hydroxy-4-propyl-furan-2-one (36.72 mg, 0.25 mmol) in DCE (2 ml). The resin was then treated with acetic acid (15 [mu] l) and sodium traacethoxyborohydride (54 mg, 0.25 mmol). The reaction was stirred at room temperature for 18 hours and washed and dried in the following solvent order: H ₂ O / DMF (1: 1), DMF, CH ₂ Cl ₂ , MeOH. The resin was suspended in a trifluoroacetic acid / CH ₂ Cl ₂ mixture (1/1) for 4 hours with vortex agitation, filtered and washed (CH ₂ Cl ₂ x 2). The filtrate was concentrated and the residue was dissolved in CH ₂ Cl ₂ (2 ml) and concentrated once more. Purification by LC-MS (Micromass-Gilson, LCZ-Platform, RP-18 column, gradient elution, CH ₃ CN / H ₂ O / TFA 1%) gave the desired compound.
[361] 1.3.3. Reductive amination and cyclization of the added aldehyde ester
[362]
[363] 150 mg of N-Fmoc-2-aminobutyramide resin (0.087 mmol) was contained in the molten polypropylene syringe. The Fmoc group was removed using 20% piperidine in DMF. To the amide resin was added aldehyde (0.5 mmol) in TMOF (2 ml). The reaction was stirred at room temperature for 18 hours, filtered and washed (CH ₂ Cl ₂ ). The resin was poured into CH ₂ Cl ₂ (swollen) and treated with sodium triacetoxyborohydride (22 mg, 0.104 mmol). The reaction was stirred at room temperature for an additional 18 hours. The resin was then washed with the following solvent and dried: H ₂ O x 6, MeOH x 6, CH ₂ Cl ₂ x 6. The resin was dissolved in trifluoroacetic acid / water mixture (95/5) for 1 hour Suspension with orbital agitation, filtration and washing (CH ₂ Cl ₂ x 2). The filtrate was concentrated and the residue was dissolved in CH ₂ Cl ₂ (2 ml) and concentrated once more. Purification by LC-MS (Micromass-Gilson, LCZ-Platform, RP-18 column, gradient elution, CH ₃ CN / H ₂ O / TFA 1%) gave the desired compound.
[364] Example 2. Synthesis of 4-substituted 2-oxo-pyrrolidinebutanamide by ring opening of 4-substituted -Lactose
[365] 2.1. Synthesis of lactone
[366] 2.1.1. Route A: 2,3-Furanone alkylation
[367] The synthesis of 4-n-butyl-butyrolactone ( 365 ) is representative:
[368]
[369] In a three-necked flask under argon, n-butyllithium (1.6M in hexane, 75ml, 0.12mol) was added to a suspension of CuI (11.42g, 0.06mol) in dry THF (80ml) and cooled to -30 ° C. After 0.5 h the solution was cooled to -78 C and TMSCI (4.75 g, 0.04 mol) and then 2,3-furanone ( 364 ) dissolved in anhydrous THF (from Aldrich, 3.36 g, 0.04 mol ) Was added dropwise. The suspension was allowed to warm to room temperature and hydrolysed with saturated ammonium chloride. The aqueous layer was extracted with AcOEt (3x), washed with water, dried with magnesium sulfate, and evaporated to dryness. The crude lactone was purified by distillation (1 mm Hg; 73-80 占 폚) to give 2.7 g of 4-n-butyl-butyrolactone ( 365 ).
[370] Alternatively, the ferrate reagent can be prepared by replacing the organolithium with an organomagnesium and the organomagnesium can be obtained by reacting an alkyl halogenide and a magnesium transition under the usual conditions for this kind of transformation have. THF can be replaced by diethyl ether (Lipshutz, BH; Sengupta, S. Org. Reactions 1991 , 41, 135]
[371] 2.1.2. Other routes
[372] Alternatively, the lactone can also be obtained by the following reaction.
[373] (I) reduction of succinate ester. 4- (Cyclopropyl) methyl-butyrolactone is prepared by alkylating monomethylsuccinate with cycloprefomethyl bromide and lithium diisopropylamide, reacting 2- (cyclopropyl) methyl-succinic acid 1-methyl ester with NaBH ₄ and because reduced by the CaCl ₂ is obtained written.
[374] (Ii) Reduction of succinic acid 1-alkyl ester 4-alkylthioester. 4-allyl-butyrolactone is obtained from ethyl 4-pententioester (synthesized from 4-pentenoic acid and ethanethiol in the presence of dicyclohexylcarbodiimide). Alkylation of ethyl 4-pentenethioate with ethyl bromoacetate and lithium diisopropylamide produces the 2-allyl-succinic acid 1-methyl ester 4-ethylthioester, which is continuously reacted with LiBH ₄ and sulfuric acid 4-allyl-butyrolactone.
[375] 2.2. Synthesis of pyrrolidone
[376] 2.2.1. Acylation / alkylation of butyramide
[377] (228, 224) of (2S) -2- (4-allyl-2-oxo-1-pyrrolidinyl) butanamide are representative:
[378]
[379] - Step 1: opening the lactone
[380] In a three-neck flask under argon, TMSI (51 ml, Aldrich) was added to a solution of crude 4-allyl-butyrolactone 366 (see § 2.1.3, Process Reference, 22.9 g, 0.181 mol) . The solution was stirred for 2 h at room temperature and was hydrolyzed with 1N HCl (300 ml). The aqueous layer was extracted with CH ₂ Cl ₂ and the combined organic phases were washed with brine, dried over magnesium sulfate and concentrated in vacuo to give crude 3- (iodo) methyl-5-hexenoic acid 367 (44.5 g) ≪ / RTI > _{^{1 H NMR (250MHz, CDCl 3}} ): 1.80-2.05 (m, 2H), 2.20 (t, 2H), 2.40-2.60 (t, 2H), 5.10-5.20 (m, 2H), 5.15-5.80 (m, 1 H).
[381] - Step 2: Chlorination of iodic acid
[382] In a three-necked flask under argon provided with a reflux condenser, a solution of thionyl chloride (25.5 ml) and unhydrogenated iodic acid (367) (44.5 g, 0.175 mol) in benzene (90 ml) was stirred at room temperature for 24 hours. Evaporation of the solvent in vacuo yields crude 3- (iodo) methyl-5-hexenoic acid chloride 368 (47 g) which is used directly in the next step without further purification. _{^{1 H NMR (250MHz, CDCl 3}} ): 1.90-2.05 (m, 2H), 2.15 (t, 2H), 2.90-3.10 (m, 2H), 3.25 (dd, 1H), 3.35 (dd, 1H), 5.10 -5.20 (m, 2H), 5.15 - 5.80 (m, 1H).
[383] Step 3: Acylation-alkylation of S-2-amino-butyramide
[384] In the three-necked flask under argon, CH ₂ S-2- amino-butyramide of Cl ₂ (300ml) of the crude acid chloride (368) (47g, 0.172mol) in the cooled CH _{0 ℃ 2 Cl 2 (470ml)} ([ _{^{α] 25 D = +19.35; 26.3g}} , 0.26mol), tetra -n- butyl ammonium bromide (2.8g, 0.0086mol), powdered mechanically stirred suspension of KOH (22.3g) and molecular sieve (29g) Lt; / RTI > The solution was stirred at -5 [deg.] C for 5 h, added powdered KOH (6.2 g) and stirring continued at -5 [deg.] C for 3 h. The reaction mixture was filtered over hyflocel and the solvent was evaporated in vacuo. The crude reaction mixture was successively purified by chromatography on silica gel (AcOEt / i-PrOH: 97/03 (v / v) and purification on chiral stationary phase (hexane / EtOH) (6.0 g (228) and 5.48 g (224), 16 and 15%, respectively) of the title compound (4-allyl-2-oxo-l-pyrrolidinyl) butanamide. (2S) -2- [4- (2-iodopropyl) -2-oxo-1-pyrrolidinyl] butanamide 225 as a white solid after recrystallization (0.22 g) and 226) < / RTI > (0.27 g).
[385] 2.2.2. Alkylation / acylation of butyramide
[386] (2S) -2- (5-nonyl-2-oxo-1-pyrrolidinyl) butanamide is representative of the synthesis of two stereoisomers:
[387] Step 1: Opening of the lactone
[388] Zinc chloride (12 mg, 0.088 mmol) was added to γ-nanolactone (0.32 ml, 2 mmol) in thionyl chloride (164 μl, 2.25 mmol) at room temperature and the mixture was stirred for 24 hours. Excess methanol was added and the reaction mixture was stirred for 10 min and concentrated under reduced pressure to give the 4-chloro-nanoic acid methyl ester used as follows.
[389]
[390] Step 2: alkylation
[391] To a solution of 4-chloro-nonanoic acid methyl ester (2 mmol) in DMF (2 ml) was successively added 2-aminobutyramide (1 g, 10 mmol), 300 mg of sodium chloride (2 mmol) and 276 mg of potassium carbonate . The mixture was stirred at 60 < 0 > C overnight. The solid was filtered and washed with CH ₂ Cl ₂ (2 x 2 ml). The filtrate was concentrated under reduced pressure to give the ether derivative used for the cyclization.
[392]
[393] Step 3: Cyclization : §1.2.2. And the conditions in § 1.2.3.
[394] 2.3. Synthesis of keto-pyrrolidin-2-one
[395] (2S) -2- [2-oxo-4- (2-oxopropyl) -1-pyrrolidinyl] butanamide (230)
[396]
[397] In a three-necked flask, oxygen was bubbled through a solution of CuCl ₂ (1.68 g, 0.0098 mol), PdCl ₂ (0.68 g, 0.0039 mol) in N-methyl-2-pyrrolidone (NMP, 40 ml) A solution of (2S) -2- [oxo-4- (2-oxopropyl) -1-pyrrolidinyl] butanamide 224 (4.13 g, 0.020 mol) in THF ). The solution was stirred under bubbling for 0.75 h, filtered through celite and evaporated in vacuo (1 mm Hg). The crude ketone was purified by silica gel (CH ₂ Cl ₂ / methyl-t-butyl ether / i-PrOH 9 / 0.9 / 0.1 (v / v)) to give (2S) -2- [2-oxo-4- (2-oxopropyl) -1-pyrrolidinyl] butanamide (230).
[398] 2.4. Induction of ketone (230)
[399] 2.4.1. Synthesis of alcohol
[400] (2S) -2 - [(4S) -4- (2-hydroxypropyl) -2-oxopyrrolidinyl] butanamide (233)
[401]
[402] - Step 1: Reduction
[403] In the three-necked flask under argon, it was added by dividing the solution (230) (9g, 0.012mol) in a EtOH (140ml) cooled to -5 ℃ NaBH _4. The solution was stirred at this temperature for 4 hours, quenched with saturated ammonium chloride and evaporated to dryness. The solids were dissolved in MeOH / CH ₂ Cl ₂ , filtered and concentrated in vacuo. The residue was purified by silica gel _{(MeOH / CH 2 Cl 2:} 90/10 (v / v)) of alcohol 369 as an oil was purified by chromatography on was generated the epimeric mixture of (2.2g, 79%). The raw mixture is directly acetylated in the next step.
[404]
[405] - Step 2: Acetylation
[406] In a three-necked flask under argon acetyl chloride (0.91 g, 0.011 mol) was added to a solution of alcohol, pyridine (0.86 ml), 4-N, N- dimethylaminopyridine (0.11 g, 0.001 mol) in CH ₂ Cl ₂ (90 ml) Solution. The solution was stirred for 5 hours, poured into saturated ammonium chloride, and the aqueous layer was extracted with CH ₂ Cl ₂ (3 ×), dried over magnesium sulfate and concentrated in vacuo to give the crude acetate, (Hexane / EtOH) to give two epimer acetates (370, 371) (1.143 and 1.17 g, respectively). For the mixture of (370) and (371) of 1/1 before chiral chromatography:
[407]
[408] - Step 3: Deacetylation
[409] In a three-necked flask under argon, a suspension of the single enantiomer of acetate (371) (1.11 g, 0.0042 mol) and K ₂ CO ₃ in EtOH was stirred at 0 ° C. for 20 hours, evaporated to dryness and the crude alcohol was chromatographed on silica gel _{/ CH 2 Cl 2: 85/15 (} v / v)) (2S) and purified by chromatography and recrystallized from acetonitrile as a white solid on -2 - [(4S) -4- ( 2- hydroxypropyl ) -2-oxopyrrolidinyl] butanamide (233) (0.67 g, 72%).
[410] 2.4.2. (230) fluorination
[411] The fluorination of the ketone 230 is used for the synthesis of 2 - [(4S) -4- (2,2-difluoropropyl) -2-oxopyrrolidinyl] butanamide 265.
[412]
[413] - Step 1: Fluorination
[414] In a Teflon flask under argon, (MeOCH ₂ CH ₂ ) ₂ NSF ₃ (1.86 g, 0.009 mol) was added in portions to a solution of (230) (0.389 g, 0.0017 mol) in CH ₂ Cl ₂ and heated at 80 ° C. for 4 hours And heated. The solution was stirred at this temperature for 4 hours, extracted with CH ₂ Cl ₂ , washed with HCl 1N, dried over MgSO ₄ , filtered and concentrated in vacuo to give tert-amide 372 ( 1.2 g). LC / MS: 365 (MH < + >). The raw mixture was used directly in the next step.
[415] - Step 2: hydrolysis and hydrolysis of ammonia
[416] In a three-necked flask under argon, a solution of crude (372) (0.28 g) in HCl 6N was heated at 60 [deg.] C for 22 hours, cooled to room temperature and then the aqueous solution was evaporated to dryness. The solid was triturated in MeCN, filtered and dried in vacuo to give the acid as a white solid (1.2 g).
[417] The crude mixture was amidated under standard conditions described in § 6.3.1 (Step 2) to give (2S) and (2R) -2 - [(4S) -4- (2,2- difluoropropyl) -2- Oxopyrrolidinyl] butanamide (87 and 13%, respectively).
[418] 2.5. (2S) -2- (2-oxo-4-propyl-1-pyrrolidinyl) butanamide (158 and 159)
[419]
[420] 2.5.1. Step 1: Reductive amination
[421] In a three-necked flask under argon, 35.3 g of 4-n-propylhydroxyfuranone (synthesized by reference to Bourguignon JJ et al; J.Med.Chem, 1988 , 31, 893-897) 0.25 mol) was added at 18 <0> C to a solution of S-2-aminobutyramide (28.1 g, 0.275 mol) in PhMe (355 ml). The solution was stirred at this temperature for 0.5 h, and precipitation occurred. The reaction mixture was stirred for 2 h, NaOH 4N (37.5 ml) was added dropwise to the suspension, and NaBH ₄ (6.2 g, 0.16 mol) in water (62 ml) was added. After 1 h, the reaction mixture was carefully padded with AcOH (30 ml), heated to 50 &lt; 0 &gt; C for 3 h and cooled to room temperature overnight. NaOH 50% w / w was added (20 ml) and the aqueous phase was extracted with PhMe (2x). The organic phase was combined, washed with brine, and concentrated in vacuo to give the crude unsaturated pyrrolidone 374 (43.4 g) as an organic oil which was used in the next step without further purification. This can be recrystallized as a white solid (DSC, onset: Mp = 72.9 [deg.] C).
[422] 2.5.2. Step 2: Singer subdivision
[423] In a three-necked flask under argon, an aqueous solution of NH ₄ COOH (8 g, 0.126 mol) was added to a suspension of 10% Pd / C (1.1 g) and crude (374) (22 g, 0.105 mol) in water (220 ml) . The suspension was stirred at 50 &lt; 0 &gt; C for 3 hours, cooled to room temperature and stirred overnight. After 18 hours, the suspension was added and heated at 50 ℃, dividing the NH ₄ COOH (8g, 0.126mol) aqueous solution. After 1.5 h, 1/3 of an aqueous solution of NH ₄ COOH (8 g, 0.126 mol) was added. The suspension was stirred for 0.5 h at 50 <0> C and 10% Pd / C (1.1 g) was added. The suspension was stirred at this temperature for 5 hours and left without stirring overnight at room temperature. The reaction mixture was filtered through celite, washed with water (30 ml) and the aqueous layer was extracted with AcOEt (3x). The combined organic phases were washed with brine and concentrated in vacuo to yield the crude pyrrolidone as white crystals (18.1 g). The two diastereomers were separated by preparative HPLC on a chiral phase (EtOH / heptane: 1/1) and after recrystallization in iPr ₂ O, two pyrrolidones (158) (9.5 g) and (159 ) (7.2 g) as a white solid.
[424] (159), that is, the A-form and the B-form were observed. Form A is typically characterized by diffraction peaks at 8.8, 9.8, 14.9, 15.0, 17.0, 17.1, 21.2, 21.4, 24.8 (2 &amp;thetas;). Form B is typically characterized by diffraction peaks at 6.50, 11.25, 19.22, 23.44, 28.47, 29.94 (2 ).
[425] 2.5.3. Synthesis of 5-hydroxy-4-propyl-furan-2-one
[426]
[427] 5-Hydroxy-4-propyl- 5H -furan-2-one (373) (15 g, 0.1 mol), ethyl acetate (260 ml) and Pd / C 5% were charged into a Parr apparatus. The mixture was degassed and hydrogen was introduced under a pressure of 35 psi. The mixture was then stirred for 2 hours at 25 &lt; 0 &gt; C. After filtration over celite, the solvent was removed under reduced pressure at 50 &lt; 0 &gt; C to yield 5-hydroxy-4-propyl-furan-2-one as a crude product (100% yield). LC / MS: 145 (MH &lt; + &gt;).
[428] Example 3. Synthesis of 4-substituted 2-oxo-pyrrolidine butanamide by alkylation of 2-oxo-pyrrolidine with ethyl 2-bromo-butanoate
[429] 3.1. Synthesis of 4-substituted 2-oxo-pyrrolidine
[430] 3.1.1.a.1. Preparation of ethyl 3- (3-chlorophenyl) -2-propenoate (375)
[431]
[432] 106.2 g (755 mmol, 1 eq.) Of 3-chlorobenzaldehyde was dissolved in 1 L of THF and cooled to 0 占 폚 in a 2 L three-necked flask under an inert atmosphere equipped with a mechanical stirrer and a dropping funnel. 341.9 g of ethyl (triphenylphosphoranylidene) acetate (980 mmol, 1.3 eq.) Were added under effective stirring and the temperature was raised to 10 &lt; 0 &gt; C. The mixture was stirred at 0 &lt; 0 &gt; C for 1 hour and allowed to stand overnight at room temperature. The mixture was concentrated to dryness, the residue was suspended in diethyl ether, the triphenylphosphine oxide was filtered off and the filtrate was concentrated to dryness. The residue was purified by PreLC (1 kg SiO ₂ , pet ether / EtOAc, 75:35) to give 191.8 g of pure (375) of 92% yield. ^{1 H NMR (250 MHz, (} CD 3) 2 SO): 1.30 (t, 3H), 4.25 (q, 2H), 6.70 (d, 1H), 7.40 (m, 2H), 7.50-7.70 (m, 2H ), 7.85 (s (broad), 1H).
[433] 3.1.1.a.2. Other methods:
[434]
[435] Alternatively, cinnamate derivatives were also synthesized by palladium-catalyzed carbometallation of acrylic derivatives. For example, ethyl (2E) -3- (5-pyrimidyl) -2-propionate (376) was obtained by reaction of ethyl acrylate and 5-bromopyrimidine in the presence of palladium acetate.
[436] 3.1.1.b. Preparation of ethyl 3- (3-chlorophenyl) -4-nitrobutanoate (377)
[437]
[438] (447 mmol, 1 eq.) Of ethyl 3- (3-chlorophenyl) -2-propenoate (375) in a 500 ml three-necked flask under inert atmosphere with a reflux condenser, magnetic stirrer and dropping funnel , 5 eq.) Of nitromethane. 70.9 ml (447 mmol, 1 eq.) Of diazabicyclo-undecene were added dropwise under effective stirring to maintain a temperature below 25 ° C (ice / water bath). The dark red mixture was stirred overnight at room temperature. The mixture was diluted with diethyl ether, washed with 1N HCl and the aqueous phase was reextracted twice with ethyl ether. The combined organic phases were dried with magnesium sulfate, filtered, concentrated to dryness to give 128.5 g of crude (377) in 99% yield, which was used in the next step. ^{1 H NMR (250 MHz, (} CD 3) 2 SO): 1.10 (t, 3H), 2.70 (dd, 1H), 2.75 (dd, 1H), 3.95 (q, 2H), 4.95 (m, 2H), 7.20-7.45 (m, 4H).
[439] 3.1.1.c. Preparation of ethyl 4-amino-3- (3-chlorophenyl) butanoate (378)
[440]
[441] In a 2 L pressurized jar under an inert atmosphere, 196 g (733 mmol) of ethyl 3- (3-chlorophenyl) -4-nitrobutanoate (377) were dissolved in 200 ml of ethanol. Of the of 700ml of ethanol 200g line dried (3x ethanol) Raney nickel was added to the suspension and the mixture was hydrogenated in a Parr be extinguisher under 20psi H ₂ pressure up to (it requires strong exothermic reaction, ice / water cooling). The mixture was degassed, filtered through Celite / Norite pad and the filtrate was concentrated in vacuo to yield 136.7 g of crude (378) yield, 78% yield, which was used in the next step.
[442] 3.1.1.d. Preparation of 4- (3-chlorophenyl) -2-pyrrolidone (379)
[443]
[444] In a 500 ml flask equipped with a reflux condenser and a magnetic stirrer, 135.7 g (561 mmol) of ethyl 4-amino-3- (3-chlorophenyl) butanoate (378) were dissolved in 200 ml of toluene, Lt; / RTI > The solution was concentrated to dryness and the residue was purified by PreLC (1 kg SiO ₂ , CH ₂ Cl ₂ / EtOH, 98: 2-> 95: 5) to give 54.4 g of pure (379) (49.2% . GC / MS: 197/197 M &lt; + &gt;.
[445] 3.1.1.f. Preparation of ethyl 2- [4- (3-chlorophenyl) -2-oxo-1-pyrrolidinyl] butanoate (380)
[446]
[447] 54.4 g (278 mmol, 1 equivalent) of 4- (3-chlorophenyl) -2-pyrrolidinone (379) was dissolved in 1.4 L of acetone in a 2 L three-necked flask under inert atmosphere with a reflux condenser, magnetic stirrer and dropping funnel. Nitrile. 64 ml (100.7 g, 556 mmol, 2 eq.) Of methyl 2-bromobutanoate were added and the temperature was raised to 50 &lt; 0 &gt; C. 22.24 g (556 mmol, 2 equivalents) of sodium hydroxide were added in portions and the hysteresis was raised to 65 &lt; 0 &gt; C. The mixture was stirred at 50 &lt; 0 &gt; C for a further hour. The mixture was concentrated to dryness, the residue was suspended in ethyl acetate, washed with water, and the aqueous phase was reextracted with ethyl acetate. The combined organic phases were dried with magnesium sulfate, filtered and concentrated to dryness. The residue was purified by PreLC (1 kg SiO ₂ , pet, ether / EtOAc, 70:30) to give 56.7 g of pure (380) (69%).
[448]
[449] 3.1.1.g. Preparation of 2- [4- (3-chlorophenyl) -2-oxo-1-pyrrolidinyl] butanamide (381)
[450]
[451] (380) of ethyl 2- [4- (3-chlorophenyl) -2-oxo-1-pyrrolidinyl] butanoate (380) was dissolved in a 1 liter three-necked flask equipped with a reflux condenser and a magnetic stirrer. Of methanol. The gaseous ammonia was bubbled into the solution and the saturated solution was re-saturated with ammonia from time to time while leaving it at room temperature for 5 days. After completion of the reaction, the solution was concentrated to dryness. The residue was purified by PreLC (1 kg SiO ₂ , CH ₂ Cl ₂ / EtOH, 97: 3) to give 50 g of pure (381) (97.8%). 82.2 g of the diastereomeric mixture was separated by chiral PrepLC (KIRALPAK AD, benzyl / EtOH, 50:50) and each pair of enantiomers was purified by chiral PrepLC (KIRALPAK AD, Benzine / EtOH, 50:50) . 4 compound was crystallized from toluene to give 16.79 g, 13.9 g, 15.84 g and 14.84 g of (202), (203), (204) and (205) respectively (overall 72%).
[452] Example 4. Synthesis of 4-substituted 2-oxo-pyrrolidine butanamide by alkylation / cyclization of 4-bromo-3-substituted-2-enoic acid ester with 2-amino-butanamide
[453] 4.1. Synthesis of 4-bromo-3-substituted-but-2-enoic acid esters, alkylation and reduction
[454] 4.1.1. The bromination of the 3-substituted crotonic acid ethyl ester
[455] The synthesis of 4-bromo-3- (2-thiophenyl) -but-2-enoic acid ethyl ester (382) is representative:
[456]
[457] 2-enoic acid ethyl ester (383) (32.88 g, 0.211 mol) in CCl ₄ (600 ml) and N-bromo-2-chloro-2-phenoxybenzoic acid in a 2 L three necked flask under argon equipped with a mechanical stirrer A degassed solution of succinimide (37.56 g, 0.211 mol) and 2,2'-aza-bis-isobutyronitrile (3.46 g, 0.021 mol) was refluxed for 6 hours, cooled to room temperature, Lt; / RTI &gt; The suspension was filtered and concentrated in vacuo to give the crude bromide which was purified by chromatography on silica gel (hexane / CH ₂ Cl ₂ : 65/35 (v / v)) to give 4-bromo- - (2-thiophenyl) -but-2-enoic acid ethyl ester (382) (36.72 g, 78%). ¹ H NMR (250 MHz, CDCl ₃ ): 3.80 (s, 3H), 4.95 (s, 2H), 6.25 (s, 1H).
[458] 4.1.2. Alkylation with 2-amino-butanamide
[459] The synthesis of 2- [2-oxo-4- (2-thienyl) -1-pyrrolidinyl] butanamide (71) is representative:
[460]
[461] 4.1.2.1. Step 1: alkylation-cyclization
[462] In a 1 L three-necked flask under argon, a solution of 4-bromo-2-thiophen-3-yl-but-2-enoic acid methyl ester (382) (36.72 g, 0.134 mol), (S) -amino-butyramide:; and stirred for 20 hours _{^{([α] 25 D 19.09˚ 31.6g}} , 0.270mol) solution at room temperature. The suspension was filtered and concentrated in vacuo to give the crude unsaturated pyrrolidone (384, 385) (43.47 g) which was used in the next step without further purification. The raw pyrrolidone can be isolated and is generally a mixture of double bond isomers (olefins in 3, 4 and 4, the first being the main).
[463]
[464] 4.1.2.2. Step 2: Reduction
[465] In a 0.5 L three-necked flask under argon, a solution of CoCl ₂ (0.062 g, 0.0005 mol) in EtOH (100 ml) -diethyleneglycol dimethyl ether (65 ml) cooled to 0 ° C and a solution of NaBH ₄ (1.75 g, 0.044 mol) Was added to the solution of the pyrrolidone (384/385) (14 g, 0.044 mol). After 0.75 h, the reaction mixture was heated under reflux for 48 h, NaBH ₄ (1.75 g, 0.045 mol) and CoCl ₂ (0.062 g, 0.0005 mol) Lt; / RTI &gt; The reaction mixture was cooled to room temperature, then hydrolyzed with saturated ammonium chloride, extracted with AcOEt, dried over magnesium sulfate and concentrated in vacuo to give the crude pyrrolidone, which was purified on silica gel (CH ₂ Cl ₂ / MeOH : 97/03 (v / v)) to give 4.15 g of 2- [2-oxo-4- (2-thienyl) -1-pyrrolidinyl] butanamide (38% &Lt; / RTI &gt; The mixture of the stereoisomers was purified by column chromatography on a chiral phase (hexane / EtOH) to give (2S) -2- [2-oxo-4- (2-thienyl) -1-pyrrolidinyl] butanamide (71) (recrystallized in AcOEt) and 72 (recrystallized in AcOEt). In this particular case, two minor impurities, (2R) -2- [2-oxo-4- (2-thienyl) -1-pyrrolidinyl] butanamide 84 (0.25 g, recrystallized from AcOEt) ) And (85) (0.44 g, recrystallized in AcOEt) were also obtained during purification.
[466] 4.2. Synthesis of azidophenylpyrrolidone
[467] The synthesis of a single enantiomer of (2S) -2- [4- (3-azidophenyl) -2-oxo-1-pyrrolidinyl] butanamide (86)
[468]
[469] 4.2.1. Synthesis of aniline
[470] 4.2.1.1. Step 1: Alkylation of (S) -2-amino-butyramide of 4-bromo-3- (3-nitrophenyl)
[471] (386) is as described in § 4.1.1. ^{1 H NMR (250MHz, (CD} 3) 2 SO): 1.30 (t, 3H), 4.20 (q, 2H), 5.15 (s, 2H), 6.45 (s, 1H), 7.75 (dd, 1H), 8.10 (dd, 1 H), 8.25 (dd, 1 H), 8.45 (d, 1 H).
[472] The alkylation was carried out according to the experimental procedure described in § 4.1.2.1. (59%). LC / MS: 290 (MH &lt; + &gt;).
[473] 4.2.1.2. Step 2: Reduction
[474] 7.22 g (0.025 mol) of 387 and Pd on charcoal (10% w / w, 0.2 g) were dissolved in EtOH (1 L) in a 2.5 L autoclave under inert atmosphere and the mixture was stirred under H ₂ pressure Hydrogenated in a Parf. After 1 hour, the mixture was degassed, filtered over Celite / Noritfat and the filtrate was concentrated in vacuo to yield the crude pyrrolidone, which was purified by column chromatography on silica gel (CH ₂ Cl ₂ / MeOH: 93/07 (v / v)) to give a mixture of diastereomers which were purified by column chromatography on a chiral (hexane / EtOH) column and eluted with HCl in EtOH (synthesis of hydrochloric acid Pyrrolidinyl] butanamide (90) (0.800 g, recrystallized in EtOH) and (3-aminophenyl) -2-oxo- 91) (1.21 g, recrystallized in EtOH) as the hydrochloride salt.
[475] 4.2.2. Synthesis of phenylradido (86)
[476] In a three-necked flask under argon, a solution of NaNO ₂ (0.232 g, 0.0037 mol) in water (1.5 ml) was added to a solution of base free (2S) -2- [4- (3- Pyrrolidinyl] butanamide 90 (0.8 g, 0.0031 mol) in anhydrous dichloromethane (2 mL) at 0 ° C. After 0.5 h at room temperature, NaN ₃ (0.220 g, And the resulting solution was stirred for 0.5 hour at 0 C. The reaction mixture was papermaking with NaOH (33% w / w) and diluted with EtOAc. The aqueous phase was oxidized to pH 5-6, The combined organic phases were dried with magnesium sulfate and concentrated in vacuo to yield the crude pyrrolidone and purified by column chromatography on silica gel (CH ₂ Cl ₂ / MeOH: 97/03 (v / v)) (2S) -2- [2-oxo-4- (3-azidophenyl) -1-pyrrolidinyl] butanamide 86 (48%) after recrystallization in MeCN, Lt; RTI ID = 0.0 &gt; The.
[477] 4.3. Synthesis of (2S) -2- [4- (3-amino-2,4,6-tribromophenyl) -2-oxo-1-pyrrolidinyl] butanamide 107
[478]
[479] In a three-necked flask under argon, a solution of Ph ₃ PCH ₂ PhBr ₃ (2.870 g, 0.048 mol) and (90) (0.420 g, 0.0016 mol) in CH ₂ Cl ₂ (10 ml) and MeOH (5 ml) was treated with NaHCO ₃ , 0.048 mol) at room temperature (organic solution). The reaction mixture was filtered and concentrated in vacuo to give the crude aniline which was purified by column chromatography on silica gel (AcOEt / ethanol 98/02 (v / v)) to give 0.38 g of the expected aniline 107 ( 47%, was produced by recrystallization hwadoem) from Et ₂ O.
[480] 4.4. (2S) -2- [4-methyl-2-oxo-1-pyrrolidinyl] butanamide (35 and 36)
[481]
[482] (35) and (36) were obtained by chiral purification of racemic (389) chiral stationary phase using EtOH and hexane as solvent. After recrystallization in i-Pr ₂ OEt, (35) was obtained as white crystals. After recrystallization from Et ₂ O, to give the 36 as a white crystal.
[483] Example 5. Synthesis of 4-substituted 2-oxo-pyrrolidinebutanamide (11) by derivation of methyl 1- [1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate Synthesis of
[484] 5.1. Synthesis of methyl 1- [1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate (11/12)
[485]
[486] These variations for producing the two esters 11 and 12 are described in § 7.0.1.
[487] 5.2. Synthesis of 1- [2S-1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylic acid (48)
[488]
[489] In a three-necked flask under argon, a solution of 1N NaOH (126 ml) was added to a solution of the enantiomerically pure ester (11) (22.62 g, 0.1 mol) in MeOH cooled to 0 ° C. After 1.5 h at this temperature, the reaction was acidified with HCl 1 N (109 mL) and the solvent was evaporated in vacuo. The residue was extracted with i-PrOH, filtered and the filtrate was concentrated in vacuo to give the crude acid (17.8 g) which was recrystallized from MeCN to give the enantiomerically pure 1- {2S-1- (Amanocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylic acid (48).
[490] 5.3. Synthesis of (2S) -2- [4- (1,3,4-oxadiazol-2-yl) -2-oxo-1-pyrrolidinyl] butanamide (50)
[491]
[492] Step 1: Reaction with hydrazine
[493] In a three-necked flask under argon, the crude hydrazide 391 (patent, 3g, 0.013mol), triethylorthoformate (2ml) and p-toluenesulfonic acid (0.010g) were heated at 10 占 폚 for 24 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to give the crude oxadiazole which was purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH: 95/5 (v / v)) to give (2S ) -2- [4- (1,3,4-oxadiazol-2-yl) -2-oxo-1-pyrrolidinyl] butanamide 50 (0.312 g).
[494] Step 2: Synthesis of oxadiazole
[495] In a three-necked flask under argon, the crude hydrazide 391 (patent, 3g, 0.013mol), triethylorthoformate (2ml) and p-toluenesulfonic acid (0.010g) solution was heated at 110 ° C for 24 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to give the crude oxadiazole which was chromatographed on silica gel (CH ₂ Cl ₂ / MeOH: 95/05 (v / v)) to give (2S) -2- [ - (1,3,4-oxadiazol-2-yl) -2-oxo-1-pyrrolidinyl] butanamide 50 (0.312 g) as an oil.
[496] 5.4. Synthesis of 1,3,4-oxadiazole derivatives
[497] Alternatively, a 1,3,4-oxadiazole derivative can be obtained from hydrazine (391). For example, hydrazine (391) can be prepared by reacting 2- [2-oxo-4- (5-sulfanyl-1,3,4-oxadiazol- Lt; / RTI &gt; with KOH and CS2 in EtOH.
[498] 5.5. Synthesis of 4-amino-pyrrolidin-2-one (392)
[499]
[500] 5.5.1. Step 1: Synthesis of carbamate (393)
[501] In a three-necked flask under argon, the enantiomerically pure 1- [2S-1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylic acid (48) (19.06 g, 0.089mol), diphenyl Pro azide (heated in 26.9g, 0.097mol) and Et ₃ 55 ℃ as the N (13.5ml) and N ₂ formation. The temperature was maintained at 55 占 폚 for 0.5 hours and 70 占 폚 for 2 hours and then cooled to room temperature. Benzyl alcohol (9.25 ml) was added, the solution was refluxed for 4 hours, cooled to room temperature and concentrated in vacuo. Raw carbamic silica gel mate _{(AcOEt / MeOH / NH 4 OH} : 95/04/01 (v / v)) and purified by chromatography to give two diastereomeric carbamates (394) on a (2.64g, 9.3 %) And 393 (11.9 g, 42%). (393):
[502]
[503] 5.5.2. Step 2: Synthesis of 4-amino-pyrrolidin-2-one (392)
[504] In the pressing of the cut 0.25L under an inert atmosphere, of 11.9g (0.037mmol) (393) and on charcoal Pd (10% w / w, 0.2g) was dissolved in EtOH (300ml), the mixture is up to 20psi H ₂ pressure &Lt; / RTI &gt; under a nitrogen atmosphere. After 20 hours, the mixture was degassed, filtered through a Celite / Norit pad, and the filtrate was concentrated in vacuo to yield the crude amine and recrystallization from PhMe to give 2- [4-amino-2-oxo -1-pyrrolidinyl] butanamide 392 (6.99 g, quant.).
[505] 5.6. Synthesis of 4-pyrrole-pyrrolidin-2-one (223)
[506]
[507] Pyrrolidinyl] butanamide (393) (6.99 g, 0.037 mol), dimethoxytetrahydrofuran (5.53 g, 0.041 mol), pyridine (50.6 ml) and AcOH (36 ml) was heated to 70 &lt; 0 &gt; C, and dissolution occurred. After 2 h at this temperature, the reaction was cooled to room temperature, concentrated in vacuo and the crude product was purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH: 95/05 (v / v) 223) (2.67 g, 30.1%).
[508] 5.7. The bromination of 4-pyrrolyl-pyrrolidin-2-one (223)
[509]
[510] Pyrrolidine-2-one (223) as a single enantiomer (1.18 g, 0.0049 mol) in THF (35 ml) was added dropwise to a 0.25 L three- Cooled to -78 [deg.] C and N-bromosuccinimide (0.877 g, 0.005 mol) was added in portions. The reaction mixture was stirred for 0.5 h, Na ₂ S ₂ O ₃ (0.9 g) was added and the NBS was papermaking. The reaction mixture was allowed to warm to room temperature, concentrated in vacuo and purified by chromatography on silica gel (EtOH / CH ₂ Cl ₂ : 05/95 (v / v)) and, after recrystallization in MeCN, (2S) -2- [4- (2-bromo-1H-pyrrol-1-yl) -2-oxo- 1 -pyrrolidinyl] butanamide 234 (1.05 g, 67%). Alternatively, using the same experimental procedure and two equivalents of N-bromo-succinimide, dibromorphol (237) can be obtained.
[511] 5.8. Synthesis of tetrazolyl derivatives
[512] Alternatively to §5.6, the reaction of 2- [4-amino-2-oxo-1-pyrrolidinyl] butanamide with triethyl orthoformate, NaN ₃ and AcOH gives 2- [ (1H-tetrazol-1-yl) -1-pyrrolidinyl] butanamide (67).
[513] 5.9. (4H-1,2,4-triazol-4-yl) derivatives
[514] Alternatively to §5.6, the reaction of 2- [4-amino-2-oxo-1-pyrrolidinyl] butanamide with pyridine and 1,2-bis ((dimethylamino) methylene) -Oxo-4- (4H-1,2,4-triazol-4-yl) -1-pyrrolidinyl] butanamide 65 and 66.
[515] Example 6. Synthesis of 2-oxo-pyrrolidine (4-substituted-2-oxo-pyrrolidinone) 4-substituted by olefination of 1- [1- (tert- butoxycarbonyl) propyl] -5- Synthesis of di-butanamide
[516] 6.1. Synthesis of 1- [1- (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxaldehyde (396)
[517] Step 1: Condensation of 2-aminobutyrate to methyl itaconate
[518]
[519] In a 1 L three-necked flask under argon, a solution of 2,2-dimethylethylethyl (S) -2-amino-butanoate (commercially available, 46.6 g, 0.268 mol) and dimethyl itaconate (83 ml, 0.59 mol) Was refluxed in MeOH (400 ml) for 20 h. The mixture was stirred at room temperature for 20 hours, concentrated in vacuo and the residue was purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH: 97/3 (v / v)) to give methyl 1 - [(1S ) -L- (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate (397) (81.6 g, quant.). Analysis of methyl 1/1 [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate (397): ¹ H NMR (250 MHz, _{(CD 3) 2 SO):} 1.05 (t, 3H), 1.44 (t, 9H), 1.60-1.65 (m, 1H), 1.65-1.90 (m, 1H), 2.40-2.65 (m, 2H solvent signal and 3H), 3.70 (s, 3H), 4.40 (dd, 1H). Alternatively, the reaction was performed with racemic 2,2-dimethylethyl-2-amino-butanoate to yield a similar yield of racemic butanamide.
[520] Step 2; Synthesis of aldehyde (396)
[521]
[522] Reduction of ester 397 to alcohol 398
[523] As the single enantiomer (397), a mixture of two diastereomers or a 1/1/1/1 mixture of four stereoisomers was used to carry out the method described in § 7.0.2. 1/1 diastereomeric mixture of tert-butyl (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] butanoate (398): GC / MS: 257 M + .
[524] Oxidation of aldehyde 396
[525] (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] butanoate (398) in 8 ml of CH ₂ Cl ₂ in a three- 4.0 g, 0.016 mol) was added to a suspension of CrO ₃ (6.2 g, 0.062 mol) in stirred pyridine (11.3 ml) / CH ₂ Cl ₂ (80 ml) at room temperature. The temperature was raised to 30 &lt; 0 &gt; C and the suspension was stirred for 0.2 hours. The suspension was filtered through celite and the filtrate was washed successively with HCl 1 N, brine, dried over magnesium sulfate and concentrated in vacuo to give the crude aldehyde, which was purified on silica gel (hexane / acetone 70/30 v / v)) to give 2.03 g of 1 - [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo-3- pyrrolidinecarboxaldehyde (396 ) (41%). Alternatively, the reaction may be carried out with a racemic ester to yield a racemic aldehyde of similar yield. 1/1 mixture of 1 - [(1S) - (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxaldehyde (396)
[526]
[527] 6.2. The olefinization of 1 - [(1S) - (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxaldehyde (396)
[528] 6.2.1. Synthesis of ethylene derivatives
[529] Alternatively to §6.2.3., The ethylene derivative may be reacted with a phosphonium salt and 1 - [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo-3-pyrrolidine Lt; / RTI &gt; can be obtained by Wittig olefination of carboxaldehyde (396). For example, 2,2- (dimethyl) ethyl ester of (2S) -2- (2-oxo-4-vinyl-1-pyrrolidinyl) butanoic acid is prepared by reacting aldehyde (396) with Ph ₃ PCH ₃ Br n-BuLi. &lt; / RTI &gt;
[530] 6.2.2. Ph ₃ P / CBr ₄ &Lt; / RTI &gt;
[531] In alternative to § 6.2.3., The halovinyl derivative can be reacted with 1 - [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo- Pyrrolidinecarboxaldehyde (396). &Lt; / RTI &gt; For example, 2,2- (dimethyl) ethyl ester of (2S) -2- (2-oxo-4- (2,2- dibromovinyl) -1- pyrrolidinyl) butanoic acid is reacted with triphenylphosphine in the presence of it was obtained from the aldehyde 396 and CBr _4.
[532] 6.2.3. (Me ₂ N) ₃ P / CF ₂ Br ₂ &Lt; / RTI &gt;
[533]
[534] (399) of the two diastereoisomers of (2S) -2- (2-oxo-4- (2,2- difluorovinyl) -1-pyrrolidinyl) butanoic acid 2,2- Synthesis is representative. In a three-necked flask under argon, (Me ₂ N) ₃ P (89.8 g, 0.55 mol) was added to a solution of CFBr ₂ (58 g, 0.25 mol) in THF (280 ml) at -78 ° C (white precipitate formation) Lt; / RTI &gt; A solution of aldehyde (396) as a 1/1 mixture of diastereoisomers (35.2 g, 0.138 mol) in THF was added dropwise to the previously formed phosphonium salt. After 1 h, the reaction mixture was filtered through celite and concentrated in vacuo. The reaction mixture was diluted with hexane, washed with brine, dried over magnesium sulfate and concentrated in vacuo to yield the crude olefin, which was purified by column chromatography on silica gel (CH ₂ Cl ₂ / MeOH 99/01 (v / v) Purification by chromatography afforded 2.2- (dimethyl) ethyl ester 399 ((2S) -2- (2-oxo-4- (2,2- difluorovinyl) 87%) of a 1/1 diastereomeric mixture of 34.6 g:
[535]
[536] 6.2.4. (nBu) ₃ P / CCl ₃ Olefinization with F
[537] Alternatively, the § 6.2.3. Halovinyl derivative can be prepared by reacting 1- [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo-3 - pyrrolidinecarboxaldehyde (396). &Lt; / RTI &gt; For example, the 2,2- (dimethyl) ethyl ester of 2- (2-oxo-4- (2- (Z) -fluorovinyl) -1-pyrrolidinyl) ₃ and n-Bu ₃ P, followed by neutralization of the intermediate vinylphosphonium by NaOH.
[538] 6.2.5. Synthesis of 4-cyano-pyrrolidone
[539] Alternatively, the 4-cyano-pyrrolidone derivative may be prepared by reacting 1 - [(1S) -1- (tert-butoxycarbonyl) propyl] -5-oxo-3- pyrrolidinecarboxaldehyde (396) Reacted with hydroxyamine, and reacted with SeO ₂ .
[540] 6.3. Aminolysis of 2,2-dimethyl-ethyl ester
[541] 6.3.1. Deprotection with trifluoroacetic acid and decarboxylation
[542] The synthesis of two diastereoisomers of (2S) -2- (2-oxo-4 (2,2-difluorovinyl) -1-pyrrolidinyl) butanamide 213 and 222 is representative:
[543]
[544] Step 1: Deprotection of 2,2- (dimethyl) ethyl ester
[545] (2S) in the three-necked flask under argon at, trifluoroacetic acid (170ml) and _{CH 2 Cl 2 (500ml) -2-} ( vinyl 2-oxo-4 (2,2-difluorophenyl) -1-pyrrolidinyl ) Butanoic acid 2.2- (dimethyl) ethyl ester (399) (31.8 g, 0.110 mol) was stirred at room temperature for 20 hours. The reaction mixture was evaporated to dryness. The residue was dissolved in toluene, re-evaporated to dryness, and trifluoroacetic acid was removed to yield 32 g of the crude acid, which was used in the next step without further purification. LC / MS: 234 (MH &lt; + &gt;).
[546] Step 2: Activation and degradation of ammonia
[547] To a solution of the acid mixture (25.6 g, 0.11 mol) in triethylamine (33.7 ml) and CH ₂ Cl ₂ (250 ml) cooled to -15 ° C in a three-necked flask under argon equipped with a mechanical stirrer was added ClCOOEt (23 ml, 0.24 mol ). Stirred for 1.5 hours, the reaction mixture was -10 ℃, while bubbling the gaseous NH ₃ through the solution, and kept the temperature below 0 ℃. The suspension was stirred at 0 &lt; 0 &gt; C for 1 hour, warmed to room temperature, filtered and the filtrate was evaporated in vacuo. The crude amide was purified by column chromatography on silica gel (CH ₂ Cl ₂ / EtOH 99/01 (v / v)) to give (2S) -2- (2-oxo-2- (2,2-difluoro Vinyl) -1-pyrrolidinyl) butanoic acid 23 g of the 1/1 diastereomer of the 2.2- (dimethyl) ethyl ester was purified by column chromatography on a chiral phase (hexane / EtOH) to give two diastereomers 213 ) (10.1 g, recrystallized from i-Pr ₂ O) and 222 (11.2 g, recrystallized from i-Pr ₂ O).
[548] 6.3.2. Alternatively, the deprotection can be carried out with bromocatechol borane.
[549] The four diastereomers of 2- (2-oxo-4- (2,2-dimethylvinyl) -1-pyrrolidinyl) butanamide 163 are 2- (2-oxo- -Dimethylvinyl) -1-pyrrolidinyl) butanoic acid 2,2- (dimethyl) ethyl ester is reacted with bromocatechol borane to give the acid, Lt; RTI ID = 0.0 &gt; (step 2). &Lt; / RTI &gt;
[550] 6.4. Synthesis of acetylene derivatives
[551] 6.4.1. Synthesis of 2- (4-ethynyl-2-oxo-1-pyrrolidinyl) butanamide (206/207)
[552]
[553] In a three-necked flask under argon, n-butyllithium (1.6 M in hexane, 116 ml) was added to a solution of 2- [4- (2,2-dibromovinyl) Pyrrolidinyl] butanamide (unmeasured stereochemistry, 10.95 g, 0.031 mol) in a 1/1 mixture of two diastereoisomers. The white suspension was stirred at this temperature for 1.5 hours, padded with MeOH (120 ml), warmed to room temperature and concentrated in vacuo. The crude alkyne was dissolved in EtOH / CH ₂ Cl ₂ (10/90 (v / v)), filtered through celite, concentrated in vacuo and the resulting solid was successively washed with silica gel (EtOH / CH ₂ Cl ₂ : 10/90 (v / v)) and chromatography on a chiral phase (EtOH / hexanes) to give 2- (4-ethynyl-2-oxo-1-pyrrolidinyl) butanamide 206 ) (0.84 g, recrystallized in PhMe) and 207 (0.44 g, recrystallized in PhMe).
[554] Alternatively, 2- (4-bromo-ethynyl-2-oxo-1-pyrrolidinyl) butanamide 267 can be prepared by reacting 2- [4- (2,2-dibromovinyl) -2- Oxo-1-pyrrolidinyl] butanamide (47) with 2 equivalents of potassium tert-butoxide in THF at low temperature (-50 ° C to 0 ° C).
[555] 6.4.2. Synthesis of 2- (4-propyn-1-yl-2-oxo-1-pyrrolidinyl) butanamide (280)
[556]
[557] A solution of methyl chloride (prepared from methyl lithium (1.5 M in ether, 6.14 ml) and ZnCl ₂ (1.25 g) in THF (15 ml) in a three-necked flask under argon) was added to a solution of CuCN (0.82 g) and LiCl (0.78 g) in dichloromethane. In a three-necked flask under argon NaH (80% in oil, 0.097 g) was added dropwise to a solution of 2- (4-bromo-ethynyl-2-oxo- 1 -pyrrolidinyl) butanamide It was added to 1g, 0.0036mol) and the solution was added ZnCl ₂ (0.50g). The amide solution was then added dropwise to the organic copper salt cooled to -78 &lt; 0 &gt; C. The reaction mixture was stirred at room temperature for 3 hours and warmed to room temperature overnight. After hydrolysis with saturated aqueous NH ₄ Cl solution, the aqueous layer is extracted with CH ₂ Cl ₂ , dried over MgSO ₄ , filtered and concentrated in vacuo to give the crude alkyne, which is purified by chromatography on a chiral phase (EtOH / hexanes) Purification by chromatography gave 2- (4-propyn-1-yl-2-oxo-1-pyrrolidinyl) butanamide 280.
[558] 6.5. Hydrogenation of olefin pyrrolidone
[559] The synthesis of a 1/1/1/1 mixture of four diastereoisomers of 2- [4- (2,2-difluoroethyl) -2-oxo-1-pyrrolidinyl] butanamide (157) to be:
[560]
[561] In a 0.25 L pressure jar under inert atmosphere, 1 g (0.0043 mmol) of 156 and Pd on charcoal (10% w / w, 0.2 g) were dissolved in EtOH (50 ml) and the mixture was hydrogenated in a Parfas. After 20 hours, the mixture was degassed, filtered through Celite / Noritfat, and the filtrate was concentrated in vacuo to yield the crude fluoroalcohol, which was recrystallized from PhMe to yield 0.75 g A 1/1/1/1 mixture of the four diastereomers of 2- [4- (2,2-difluoroethyl) -2-oxo-1-pyrrolidinyl] butanamide (157).
[562] 6.6. Synthesis of 2- [4- (5-methyl-1,3-oxazal-2-yl) -2-oxo-1-pyrrolidinyl] butanamide
[563]
[564] Step 1: Hydrolysis of the ester
[565] In a three-necked flask under argon, NaOH 1N (39 ml) was added to a solution of methyl 1- [1- (tert-butyloxycarbonylamino) methyl] Propoxylcarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate (397). The solution was stirred for 0.5 h, evaporated to dryness and the pH was oxidized to 1 with HCl 1N. The aqueous layer was extracted with AcOEt, dried over MgSO _4, filtered and concentrated under vacuum to produce a crude acid (400) (8.45g) as a white solid and was used without further purification in the next step.
[566]
[567] Step 2: Synthesis of amide (401)
[568] In a three-necked flask under argon, ClCOOEt (0.50 ml, 0.005 mol) was added to a solution of the acid (400) (0.678 g, 0.0025 mol) in triethylamine (0.77 ml) and CH ₂ Cl ₂ . The reaction mixture was stirred at -10 DEG C for 1.5 hours and propargylamine (0.36 mL) was added to the solution, keeping the temperature below 0 DEG C. The suspension was stirred at 0 &lt; 0 &gt; C for 1 hour, warmed to room temperature, filtered and the filtrate was evaporated in vacuo. The crude amide was purified by column chromatography on silica gel (CH ₂ Cl ₂ / MeOH 98/02 (v / v)) to give 0.8 g of propargyl amide as a 1/1/1/1 mixture of four diastereomers (401).
[569]
[570] Step 3: Synthesis of oxazole (402)
[571] A solution of amide 402 (0.77 g, 0.0025 mol) in AcOH (40 ml) and Hg (OAc) ₂ (0.048, 0.00015 mol) in a three-necked flask under argon was refluxed for 1 hour, the reaction was cooled to room temperature, concentrated, and hydrolyzed with saturated Na ₂ CO _3. The aqueous layer was extracted with CH ₂ Cl ₂ and the organic phase was washed with brine, dried over MgSO ₄ , filtered and concentrated in vacuo to yield the crude compound and purified on silica gel (hexane / AcOEt: 50/50 v / v )) Gave pure oxazole 402 (0.15 g, 20%). GC / MS: 308 (M +) This may be converted to (62) and (63) by ammoniacysis analogously to 6.3.1.
[572] 6.7. Synthesis of tetrazole
[573] 6.7.1. Synthesis of unsubstituted tetrazoles
[574]
[575] In a three-necked flask under argon, a solution of racemic nitrile 403 (2.66 g, 0.011 mol), NaN ₃ (4.8 g, 0.073 mol) and Et ₃ N-hydrochloric acid (10.12 g) , &Lt; / RTI &gt; cooled to room temperature and evaporated in vacuo. The crude product was purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH / AcOH: 90/08/02 (v / v)) to give racemic tetrazole as a 1/1/1/1 mixture of diastereomers Ester 404 (3.42 g, 0.010 mol). LC / MS: 295 (MH &lt; + &gt;).
[576] 6.7.2. Alkylation of tetrazole
[577]
[578] (5.6 g, 0.019 mol), K ₂ CO ₃ (2.88 g) and MeI (1.3 ml) in DMF (60 ml) were stirred at room temperature for 29 hours and treated in vacuo &Lt; / RTI &gt; The crude mixture was purified by chromatography on silica gel (MTBE / hexane: 50/50 (v / v)) to give two active isomers 405 (1.98 g, 34%) and 406 (1.03 g, 17%). LC / MS: 309 (MH &lt; + &gt;).
[579] 6.8. Synthesis of Thiazole
[580] 6.8.1. Synthesis of thioamide
[581]
[582] 6.8.1.1. (397)
[583] In a 0.51 L three-necked flask equipped with a reflux condenser, a magnetic stirrer and a submerged addition gas tube, 10 g (0.035 mol) of (397) was dissolved in 100 ml of methane. The saturated solution was then allowed to stand at room temperature for one day, while the ammonia gas was bubbled through the solution and re-saturated with ammonia from time to time. After the reaction was complete, the solution was concentrated in vacuo to yield the crude amide 407 (9.6 g, 100%).
[584]
[585] 6.8.1.2. Synthesis of thioamide (408)
[586] In a three-necked flask under argon, the crude amide 407 (6 g, 0.022 mol), P ₄ S ₁₀ (4.93 g, 0.011 mol) and NaHCO ₃ (3.73 g) in MeCN (100 ml) . The reaction mixture was filtered, concentrated in vacuo and the crude thioamide was purified by chromatography on silica gel (AcOEt / hexane: 50/50 (v / v)) to afford thioamide 408 (3.7 g, 0%). GC / MS: 286 (M &lt; + &gt;).
[587] 6.8.2. Synthesis of Substituted Thiazoles
[588]
[589] In a three-necked flask under argon, Al ₂ O ₃ (12 g), 1-bromo-2-dimethoxyprop-2-ene (0.85 ml) in PhMe (100 ml) A solution of thioanide (408) (1.5 g, 0.005 mol) as a 1/1 mixture was refluxed for 3 hours. The reaction mixture was cooled to room temperature, filtered and concentrated in vacuo to give the crude thiazole 409 (0.5 g, 30%) which was used in the next step without further purification. GC / MS: 324 (M &lt; + &gt;).
[590] 6.8.3. Synthesis of unsubstituted thiols
[591] Alternatively, unsubstituted thiazoles can be obtained by reacting thioamide 408 with Al ₂ O ₃ and bromo-acetaldehyde (originally produced from bromo-2,2-dimethoxyethane under acidic conditions) .
[592] 6.8.4. Synthesis of 1,2,4-thiadiazol-5-yl-derivative
[593] Alternatively, the 1,2,4-thiadiazol-5-yl-derivative may be prepared by reacting the thioamide 408 with N, N-dimethyl-acetamide dimethylacetal and crystallizing in the presence of pyridine Can be obtained.
[594] 6.9. Synthesis of 2,2-dimethylethyl ester (410) of 2- [2-oxo-4- (3-pyridinylcarbonyl) -1-pyrrolidinyl]
[595]
[596] In a three-necked flask under argon, SOCl ₂ (0.56 ml) was added to a solution of the acid (400) (1.90 g, 0.007 mol) in PhMe (20 ml) at room temperature. The reaction mixture was refluxed for 1.5 hours and became yellow. After cooling to room temperature, PdCl ₂ (PPh ₃ ) ₂ (0.25 g, 0.00035 mol) and 3-trimethylstannyl-pyridine (1.7 g, 0.007 mol) were added in portions and the reaction mixture refluxed for 0.5 h, It was cooled down, and water was restrained. The aqueous layer was extracted with dichloromethane and the combined organic phases were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo (3.2 g). The crude ketone was purified by column chromatography on silica gel (CH ₂ Cl ₂ / MeOH 97/03 (v / v)) to give 1.3 g of ketone 410 as a 1/1/1/1 mixture of four diastereomers, &Lt; / RTI &gt; LC / MS: 333 (MH &lt; + &gt;).
[597] Example 7. Synthesis of 2- (4-substituted-2-oxo-pyrrolidinyl) -butanamide by substitution of activated 2- (4-hydroxymethyl-2-oxo-pyrrolidinyl) synthesis
[598] 7.0. Synthesis of starting alcohols
[599] 7.0.1. Synthesis of ester-amide
[600] 7.0.1.a. Synthesis of methyl 1 - [(1S) -1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinecarboxylate (11/12)
[601]
[602] (12 moles, 1 eq.) Of (2S) -2-aminobutanamide and 1912 ml (2150 g, 13.2 moles, 1.1 eq.) Of dimethyl itaconate in a 10 L three-necked flask under inert atmosphere equipped with a mechanical stirrer and a reflux condenser Was dissolved in 6.13 L of MeOH. The mixture was refluxed for 10 hours and slowly cooled to 20 &lt; 0 &gt; C over 4 hours. Filtered, the precipitate was washed with MeOH, and the combined organic phases were concentrated to dryness to give 3.283 g of crude intermediate (74%).
[603] In a 20 L three-necked flask under an inert atmosphere equipped with a mechanical stirrer and a Rashig column and a distillation arm, the crude intermediate and 84.7 g (891 mmol, 0.1 eq.) Of 2-hydroxypyridine were dissolved in 11.6 L of toluene. The mixture was refluxed and the methanol formed until 480 ml was collected was distilled for 8 hours. The temperature in the vessel reached 112 ° C. The mixture was cooled, concentrated and dried to yield 2.187 g of the crude amide ester as a mixture of diastereomers at a ratio of 57.5 / 42.5.
[604] The two diastereomers were separated by chiral phase purification liquid chromatography (Chiralpak AD 100 * 500 mm, EtOH / H ₂ O 99.9: 0.1) and the eluent was concentrated to dryness to give 968 g of crude 12 Eluted) and 1.052 g of crude 11 (second eluted). The raw material 12 was not crystallized, which dissolved in 1.5 L of EtOH and was kept in this state for further use. The crude (11) was recrystallized from 2 L of EtOAc to yield 676 g of pure (11).
[605] Alternatively, the methyl 1 - [(1S) -2-amino-1-methyl-2-oxoethyl] Aminocarbonyl) butyl] -5-oxo-3-pyrrolidinecarboxylate, methyl 1 - {(1S) -1 - [(methylamino) carbonyl] propyl} -5- Carboxylates are prepared in a similar manner.
[606] 7.0.2. Synthesis of alcohol-amide
[607] 7.0.2.a. Synthesis of (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] butanamide (6)
[608]
[609] In a 2 L three-necked flask under an inert atmosphere equipped with a mechanical stirrer and a reflux condenser, 133 g (583 mmol, 1 equivalent) of (2S) -2- (4-methoxycarbonyl- pyridinyl) butane was added to the amide 11 in 300ml of EtOH, and the mixture was cooled to 0 ℃, while the temperature was maintained at 2 to 4 ℃ over the solid NaBH ₄ of 66.2g (1.74mole, 12 eq.) 1.5 hours . After 2 hours, the temperature was raised to 12 占 폚 for 1 hour and again lowered to 2-4 占 폚. 240ml of a saturated solution of NH ₄ Cl, then added, dropwise over 1 hour 120ml of acetone and the mixture was allowed to stand overnight at room temperature. The mixture was filtered, the precipitate was washed with 3x70ml EtOH, and the combined organic fractions were concentrated to dryness to yield 148g of raw (6). It was suspended in 300 ml of CH ₂ Cl ₂ , stirred for 30 minutes, filtered, washed with ₂ × 100 ml of CH ₂ Cl ₂ and dried to yield 114 g of pure (6) (98%).
[610] Alternatively, a mixture of (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] -1-pyrrolidinyl] pentanamide, (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] -N-methylbutanamide was prepared in a similar manner.
[611] 7.1. PPh ₃Synthesis by direct conversion using
[612] 7.1.1. Synthesis of (2S) -2- [4- (iodomethyl) -2-oxo-1-pyrrolidinyl] butanamide (10)
[613]
[614] In a 10 L three-necked flask under an inert atmosphere equipped with a mechanical stirrer and a reflux condenser, 400 g (2 moles, 1 equivalent) of (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] Amide (6) was dissolved in 3 L of acetonitrile. 629 g (2.4 moles, 1.2 eq.) Of triphenylphosphine were added and 608 g (2.4 moles, 1.2 eq.) Of iodine were added in portions over three 5 minutes. The mixture was heated to 60 &lt; 0 &gt; C in 30 min and stirred at this temperature for 5 h. After cooling, the mixture was concentrated to dryness and the residue was suspended in 750 g of Na ₂ S ₂ O ₃ solution in 10 L of water and stirred at 50 ° C. for 4 hours. The precipitate was filtered off and washed with 3 x 11 water. Treated with 1 kg NaCl in a mixed organic phase and extracted with 6 x 11 CH ₂ Cl ₂ . Dry the organic phase was mixed with MgSO _4, filtered, and concentrated to dryness and the raw generation (10) of 482g. Crystallization from toluene. The various yields were recrystallized together from ethyl acetate to yield 425 g of pure (10) (68%).
[615] Alternatively, a solution of (2S) -2- [4- (iodomethyl) -2-oxo-1-pyrrolidinyl] Pyrrolidinyl] propanamide (110), (2S) -2- [4- (Iodomethyl) -2-oxo-pyrrolidin- 1 -yl] pentanamide Pyrrolidinyl] butanamide (8), (2S) -2- [4- (chloromethyl) -2-oxo- Oxo-1-pyrrolidinyl] butanamide (30) was prepared in a similar manner.
[616] 7.1.2. Synthesis of (2S) -2- [2-oxo-4- (phenoxymethyl) -1-pyrrolidinyl] butanamide (18)
[617]
[618] (5 mmole, 1 eq.) Of (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] butane in a 50 ml three-necked flask under inert atmosphere equipped with a magnetic stirrer and a dropping funnel The amide (6) was dissolved in 20 ml of THF and cooled to 0 &lt; 0 &gt; C. 517 mg of phenol, 0.8 ml (960 mg) of diethyl azodicarboxylate and 1.44 g of triphenylphosphine (5.5 mmole, 1.1 equivalents each) were successively added and the mixture was stirred for 2 hours. The mixture was concentrated to dryness and purified by Prep LC (500 kg SiO ₂ , CH ₂ Cl ₂ / EtOH, 97.5: 2.5) to give 1.1 g of pure (10) (80%) and crystallize from ethyl acetate.
[619] 7.2. Synthesis by substitution of mesylate
[620] 7.2.1. Synthesis of {1- [(1S) -1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinyl} methyl methanesulfonate (37)
[621]
[622] (569 mmole, 1 eq.) Of (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidone in a 4 L three-necked flask under inert atmosphere with a mechanical stirrer, dropping funnel and reflux condenser Dinyl] butanamide (6) was dissolved in 1 L of CH ₂ Cl ₂ and cooled to 0 ° C. 158.5 ml (115 g, 2 eq.) Of anhydrous triethylamine were added in portions and the solution of methanesulfonyl chloride in 190 ml of CH ₂ Cl ₂ was added dropwise over 1 hour, keeping the temperature below 4 ° C. After 4 hours, 7.5 ml of methanesulfonyl chloride and 15 ml of triethylamine were added and the mixture was kept in the refrigerator overnight. The mixture was filtered, the residue was washed with CH ₂ Cl ₂ , and the combined organic phases were concentrated to dryness to yield 216 g of crude (37). This was purified in several batches by Prep LC (1 kg SiO ₂ , CH ₂ Cl ₂ / EtOH, 100: 1-> 96: 4) to give 109 g of pure (37) (69%). Alternatively, {1 - [(1S) -1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinyl} methyl 4-methylbenzenesulfonate (31) was prepared in a similar manner.
[623] 7.2.2. Synthesis of (2S) -2- [4- (azidomethyl) -2-oxo-1-pyrrolidinyl] butanamide (32)
[624]
[625] In a 3 L three-necked flask equipped with a mechanical stirrer and a reflux condenser, 89.7 g (322 mmole, 1 equivalent) of dml {1 - [(1S) -1- (aminocarbonyl) propyl] Lt; / RTI &gt; ylmethyl methanesulfonate (37) was dissolved in 300 ml of acetonitrile. 27.3 g (419 mmole, 1.3 eq.) Of sodium azide was added in one portion with 150 ml of acetonitrile. The mixture was refluxed for 20 min and stirred overnight. 3.1 g (48 mmole, 0.2 eq.) Of sodium azide was added and reflux continued for a total of 44 hours. After cooling to 10 ° C, the mixture was filtered, the precipitate was washed with 3 x 50 ml of acetonitrile, and the combined organic fractions were concentrated to dryness to yield 77.3 g of crude (32). This was crystallized from 150 ml of ethyl acetate at 10 캜 to give 60 g of crude (32) (82%).
[626] Alternatively, a mixture of (2S) -2- [4- (fluoromethyl) -2-oxo-1-pyrrolidinyl] butanamide 44, Yl) methyl) -1-pyrrolidinyl] butanamide (39), (2S) -2- [ (2-oxo-4- (1H-1,2,4-triazol-1-ylmethyl) -1-pyrrolidinyl] butanamide 55 ), 2- (2-oxo-4- (1H-1,2,3-triazol-1-ylmethyl) (1-pyrrolidinylmethyl) -2-oxo-1-pyrrolidinyl} butanamide (24) Pyrrolidinyl] butanamide (15), an alcohol derivative in which (2S) -2- [2-oxo-4- (4-thiomorpholinylmethyl) For example, from mesylate, tosylate or halide in a similar manner.
[627] 7.3. Other Composites
[628] 7.3.1. Synthesis of {1- [(1S) -1- (aminocarbonyl) propyl] -5-oxo-3-pyrrolidinyl} methyl nitrate (38)
[629]
[630] (26 mmole, 1 eq.) Of (2S) -2- [4- (iodomethyl) -2-oxo-1-pyrrolidinyl] pyrimidine in a 500 ml three-necked flask under inert atmosphere equipped with a mechanical stirrer and a reflux condenser. Butanediol (10) was dissolved in 250 ml of acetonitrile. 4.86 g (28.6 mmole, 1.1 eq.) Of silver nitrate was added and the mixture was refluxed. After 2 hours, 440 mg (2.8 mmole, 0.1 eq.) Of silver nitrate was added and refluxing was continued for a total of 4 hours. After lowering the temperature, the mixture was concentrated to dryness and purified by PrepLC (200 g SiO ₂ , CH ₂ Cl ₂ / MeOH / NH ₄ OH, 96: 5.4: 0.6) to give 5.7 g of crude 38 . This was crystallized from 50 ml of ethyl acetate to give 4.13 g of pure (38) (65%).
[631] 7.3.2. Synthesis of 2- {4 - [(benzyloxy) methyl] -2-oxo-1-pyrrolidinyl} butanamide (153/154)
[632]
[633] 7.3.2.a. Synthesis of tert-butyl (2S) -2- {4 - [(benzyloxy) methyl] -2-oxo-1-pyrrolidinyl] butanoate
[634] 1.1 g (60%, 27.5 mmole, 1.1 eq.) Of sodium hydroxide was suspended in 60 ml of DMF and the mixture was cooled to 0 占 폚 in a 100 ml three-necked flask under an inert atmosphere equipped with a magnetic stirrer and a reflux condenser. (24.8 mmole) of tert-butyl (2S) -2- [4- (hydroxymethyl) -2-oxo-1-pyrrolidinyl] butanoate (398) in 10 ml of DMF was carefully added Respectively. After 10 min, 3.3 ml (4.75 g, 27.8 mmole, 1 eq.) Of benzyl bromide in 10 ml of DMF were added and stirred continuously at 0 &lt; 0 &gt; C for 3 h and at room temperature for 3 h. The mixture was concentrated to dryness, the residue was suspended in brine / CH ₂ Cl ₂ , poured gently, and extracted with CH ₂ Cl ₂ . The combined organic phases were dried over MgSO ₄ , concentrated to dryness and the residue was purified by PrepLC (1 kg SiO ₂ , hexane / MTBE, 40: 60-> 0: 100) to give two fractions of t-Bu and benzyl ester (Total yield, 37%). It is used in the other step 7.3.1.b. ^{1 H NMR (250MHz, (CDCl} 3)): 0.85 (t, 3H), 1.44 (s, 9H), 1.55-1.95 (m, 2H), 2.10 (dd, 1H), 2.45 (dd, 1H), 2.55 2H), 7.20-7.40 (m, 5H). &Lt; RTI ID = 0.0 &gt;
[635] 7.3.2.b. Synthesis of 2- [4 - [(benzyloxy) methyl] -2-oxo-1-pyrrolidinyl}
[636] In a 50 ml three-necked flask under an inert atmosphere equipped with a magnetic stirrer and a reflux condenser, 1.75 g of benzyl ester loaded fraction was dissolved in 20 ml of MeOH. The ammonia gas was bubbled into the solution and the saturated solution was maintained at room temperature for 24 hours while occasionally re-saturated with ammonia. After completion of the reaction, the solution was concentrated to dryness and purified by PrepLC (1 kg SiO ₂ , CH ₂ Cl ₂ / MeOH, 98: 2-> 90:10) to give two diastereomers.
[637] In a 25 ml three-necked flask under an inert atmosphere equipped with a magnetic stirrer and a reflux condenser, 1.24 g of the t-Bu ester loaded fraction was dissolved in 16 ml of a 1: 1 mixture of CH ₂ Cl ₂ / TFA and 24 Hour. The solution was concentrated to dryness and the residue was dissolved in 10 ml of CH ₂ Cl ₂ . 1.2 ml (2.2 eq.) Of triethylamine were added and the mixture was cooled to -20 &lt; 0 &gt; C. 780 [mu] l_ of ethyl chloroformate was added dropwise, and the mixture was slowly warmed to -10 [deg.] C over 1.5 hours. Thereafter, the ammonia gas was bubbled into the solution for 0.5 hour, and the mixture was allowed to stand overnight at room temperature. It was filtered, the precipitate was washed with CH ₂ Cl ₂ and the combined organic fractions were concentrated to dryness and purified by PrepLC (1 kg SiO ₂ , CH ₂ Cl ₂ / MeOH, 98: 2-> 90:10) Two diastereoisomers were generated. The first and second eluted diastereomers from both were combined and crystallized from toluene to yield 305 mg of pure (153) and 480 mg of pure (154), respectively (11% overall).
[638] 7.3.3. Synthesis of (2S) -2- {4 - [(5-methyl-1H-1,2,3-triazol-1-yl) methyl] -2-oxo-1-pyrrolidinyl}
[639]
[640] (4.44 mmole, 1 eq.) Of (2S) -2- [4- (azidomethyl) -2-oxo-1-pyrrolidinyl] pyrimidine in a 50 ml three-necked flask under inert atmosphere equipped with a magnetic stirrer and a reflux condenser. Butanamide 32 was suspended in 20 ml of toluene. 1.55 g (4.88 mmole, 1.1 eq.) Of 1- (triphenylphosphoranylidene) acetone were added and the mixture was heated to 80 <0> C for 24 hours. After cooling, the mixture was concentrated to dryness and purified by PrepLC (1 kg SiO ₂ , CH ₂ Cl ₂ / MeOH / NH ₄ OH, 94.5: 5: 0.5). This was suspended in 15 ml of water to give 240 mg of pure (52) as a clear oil (42%).
[641] 7.3.4 Synthesis of (2S) -2- [4- (isothiocyanatomethyl) -2-oxo-1-pyrrolidinyl] butanamide (49)
[642]
[643] In a 500 ml pressure jar under an inert atmosphere, 900 mg of 10% Pd adsorbed on charcoal was suspended in 100 ml of ethanol. (2S) -2- [4- (azidomethyl) -2-oxo-1-pyrrolidinyl] butanamide (32) in 150 ml of ethanol was added and the mixture was stirred for 2 hours It was hydrogenated in a Parfas under max. 30 psi H ₂ pressure. The mixture was degassed and the filtrate was concentrated to dryness to give 7.93 g of crude 412 (100% yield) which was used in the next step. GC / MS: 199 (M &lt; + &gt;).
[644] 7.3.4.a. Synthesis of (2S) -2- [4- (isothiocyanatomethyl) -2-oxo-1-pyrrolidinyl] butanamide (49)
[645] In a 100 ml three-necked flask under an inert atmosphere equipped with a magnetic stirrer and a reflux condenser, 4.5 g (22.7 mmole, 1 equivalent) of thiocarbonylimidazole was dissolved in 25 ml of DMF and the mixture was cooled to 0 &lt; 0 &gt; C. (22.7 mmole, 1 eq.) Of (2S) -2- [4- (aminomethyl) -2-oxo-1-pyrrolidinyl] butanamide (412) in 25 ml of DMF was added dropwise And the mixture was stirred at room temperature for 3 hours and left overnight. By _{(0.6 350g SiO 2, CH 2} Cl 2 / MeOH / NH 4 OH, 93.4:: 6) The mixture was concentrated to dryness, the residue was dissolved in toluene of 20ml and dried again concentrated, and the residue PrepLC The solution was purified to yield 3.1 g of crude (49). Trituration in 20 ml of ether, filtration and crystallization of the residue (1.9 g) from 15 ml of acetonitrile gave 1.2 g of pure (49) (22%).
[646] Compounds of formula I shown in the table below may be prepared analogously or in any other manner as described herein.
[647] In the table, the stereochemical information was recorded in two columns specified as " constituent data ". These two columns indicate whether the compound is ACHIRAL, pure enantiomer (PURE), racemic (RAC), or a mixture of two or more stereoisomers (MIXT), possibly in unequal proportions . The first column shows the stereochemical assignment for each recognized center after IUPAC numbering used in the previous column. The numbers alone indicate the presence of two forms at this center. 'R' or 'S' after the number indicates the absolute form known at this center. The '§' after the number represents the only unrecognized absolute form present in this center. The first letter (A, B, C, D) is a means for distinguishing between various enantiomers or racemates of the same structure.
[648] In the table, the melting point is measured in most cases by initiation of the DSC curve. Visual (melt measurement) If the melting point is presented, the values are given in parentheses.
[649] In the table, the number in the column 'Synthesis' is the synthetic method used for the most important felts. In order to obtain a similar compound, a slight modification is required. Such modifications are known to those skilled in the art of organic synthesis.
[650]
[651]
[652]
[653]
[654]
[655]
[656]
[657]
[658]
[659]
[660]
[661]
[662]
[663]
[664]
[665]
[666]
[667]
[668]
[669] Example 8: LBS binding assay
[670] [LBS is going Betty La Im ride binding sites (L evetiracetam B inding S ite) . (M.Noyer et al., Eur. J. Pharmacol., 286 (1995) 137-146).
[671] The inhibition index (K _i ) of the compound was determined by competitive binding experiments by measuring the binding of radioligands at uniform concentrations of unlabeled test substances at various concentrations. The concentration of the test substance which inhibits specific binding of radioligand by 50% is referred to as IC ₅₀ . The parallel dissociation constants K _i are proportional to IC _{50 and} are calculated using the Cheng and Prusoff equation (Cheng Y. et al., Biochem. Pharmacol. 1972, 22, 3099-3108).
[672] The concentration range generally includes 6 log units with various steps (0.3 to 0.5 log). The analysis is performed singly or doubly, and each K _iThe measurements were performed on two different samples of the test material.
[673] The cerebral cortex from 200-250 g male Sprague-Dawley rats was suspended in 20 mmol / l Tris-HCl (pH 7.4), Potter S homogeniser in 250 mmol / l sucrose (A buffer) ) (10 strokes at 1000 rpm; homogenized using Braun, Germany; all processes were carried out at 4 ° C. The homogenate was centrifuged at 30,000 g for 15 minutes. The obtained raw membrane pellets were suspended in 50 mmol / l Tris-HCl (pH 7.4) (B buffer), incubated at 37 DEG C for 15 minutes, centrifuged at 30,000 xg for 15 minutes and washed twice with the same buffer. Resuspended in A buffer at a protein concentration of 25 mg / ml and stored in liquid nitrogen.
[674] The membrane (protein / analysis of _{150-200㎍), 2mmol / l MgCl 2} , 1 to 2 10 ^-9 mol / l of ^{[3 H] -2- [4- (} 3- O map phenyl) -2-oxo -1-pyrrolidinyl] butanamide and incubated for 120 minutes at 4 ° C in 0.5 ml of 50 mmol / Tris-HCl buffer (pH 7.4), the concentration of the test substance being increased. Nonspecific binding (NSB) is defined as the remaining binding observed in the presence of a concentration of the reference substance that is essentially binding to all receptors (e. G., ^10-3 mol / l betiracetam). The membrane-bound and free radioligand was a glass fiber filter (equivalent to Whatman GF / C or GF / B pre-wetted with 0.1% polyethyleneimine and 10 ^-3 mol / RTI ID = 0.0 &gt; VEL) &lt; / RTI &gt; to reduce nonspecific binding. The sample and the filtrate were rinsed with at least 6 ml of 50 mmol / l Tris-HCl (pH 7.4) buffer. The total filtration process did not exceed 10 seconds per sample. The radioactivity trapped in the filters was counted by liquid scintillation in a [beta] -counter (Tri-Carb 1900 or TopCount 9206, Camberra Packard, Belgium, or other equivalent counter). Data analysis was performed by a computerized nonlinear curve fitting method using a set of equations describing several coupled models for estimating populations of independent non-interacting receptors according to the law of mass.
[675] The pKi of the compound according to the present invention is 6.0 or more. Specific affinities can be determined by the number of amino acid residues of the compound Nos. 8, 9, 10, 22, 23, 27, 30, 31, 32, 33, 38, 40, 41, 43, 46, 47, 49, 64, 71, 72, 151, 152, 156, 157, 158, 159, 159, 159, 175, 176, 180, 181, 185, 187, 188, 195, 196, 197, 198, 200, 201, 204, 209, 211, 213, 214, 215, 219, 221, 222, 223, 224, 225, 226, 228, 229, 234, 250, 251, 252, 264, 265, 267, 304, 306, 350 and 351.
[676] Example 9: Animal model of acoustically sensitive mouse
[677] The purpose of this experiment was to evaluate the anticonvulsant effects of compounds in acoustic models of mice that are sensitive to sound, that is, in retrospective animal models with reflex seizures. In the primary systemic epilepsy of these models, seizures occurred without electrical or chemical stimulation and types of seizures are at least partially similar to clinically phenomenal human episodes (Loescher W. & Schmidt D., Epilepsy Res. (1998) , 2, 145-181, Buchhalter JR, Epilepsia (1993), 34, S31-S41).
[678] It was originally selected by Dr. Lehmann of the Laboratory of Acoustic Physiology, Paris and has been grown at the UCB Pharma Sector husbandry unit since 1978 A male or female genetically sound-sensitive mouse (14-28 g; N = 10) derived from the DBA strain was used. Experimental design consisted of several groups, one group was given a control carrier and the other groups were given different doses of the test compound. Compounds were administered intraperitoneally 60 minutes prior to inducing high-frequency inhalation. The range of doses dosed has a logarithmic series and generally has 1.0 x ^10-5 mol / kg and 1.0 x ^10-3 mol / kg, but can be tested with fewer or more doses as needed.
[679] For testing, the animals were placed in a small single room per animal in a chamber where the sound was weakened. After 30 seconds of adaptation, an acoustic stimulus (90 dB, 10-20 kHz) was applied for 30 seconds through a loudspeaker located above each of us. During this period, mice were observed and three states of seizure status, wild running, intermittent seizures and ankylosing spasms were recorded. The proportion of mice protected against wild running, intermittent convulsions and rigorous convulsions was calculated, respectively.
[680] For the active compound, the dose leading to a 50% protection for the control group with an ED50 value, i.e. a confidence limit of 95%, was calculated by dividing the ratio of mice protected against each triad of seizure activity by Probit Analysis) (SAS / STAT ^® Software, version 6.09, PROBIT fixed).
[681] The ED50 value of the compound according to the present invention was 1.0E-0.4 or less. Particularly, the compound having a promising activity is Compound No. 8, 9, 10, 22, 23, 27, 30, 31, 32, 33, 38, 40, 41, 46, 47, 64, 71, 72, 186, 180, 181, 187, 188, 195, 169, 169, 162, 163, 164, 165, 166, 180, 196, 197, 198, 200, 201, 204, 205, 207, 209, 211, 212, 213, 214, 215, 219, 221, 222, 223, 224, 226, 228, 229, 234, 252, 264, 265, 267, AA1, AA2, AA3, AA4 and AA5.

权利要求:
Claims (39)
[1" claim-type="Currently amended] Claims 1. A compound of formula (I): &lt; EMI ID =

In this formula,
X is -CA ¹ NR ⁵ R ⁶ , -CA ¹ OR ⁷ , -CA ¹ -R ⁸ or CN;
A ¹ and A ² are independently oxygen, sulfur or -NR ⁹ ;
R ¹ is hydrogen, alkyl, aryl or -CH ₂ -R ^1a , wherein R ^1a is aryl, heterocycle, halogen, hydroxy, amino, nitro or cyano;
R ² , R ³ and R ⁴ are the same or different and each is independently selected from the group consisting of hydrogen, halogen, hydroxy, thiol, amino, nitro, nitrooxy, cyano, azido, carboxy, amido, Alkyl, alkenyl, alkynyl, ester, ether, aryl, heterocycle or oxy derivative, thio derivative, amino derivative, acyl derivative, sulfonyl derivative or sulfinyl derivative;
R ^2a , R ^3a and R ^4a are the same or different and each independently hydrogen, halogen, alkyl, alkenyl, alkynyl or aryl;
R ⁵ , R ⁶ , R ⁷ and R ⁹ are the same or different and each independently is hydrogen, hydroxy, alkyl, aryl, heterocycle or oxy derivative;
R ⁸ is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, heterocycle or thio derivative;
Provided that at least one of R ² , R ³ , R ⁴ , R ^2a , R ^3a and R ^4a is a group other than hydrogen,
When the compound is a mixture of all possible isomers, X is -CONR ⁵ R ⁶ , A ² is oxygen and R ¹ is hydrogen, methyl, ethyl or propyl, the substituents on the pyrrolidine ring may be mono-, Methyl, or mono-ethyl;
^{R 1, R 2, R 4} , R 2a, R 3a and R ^4a are each hydrogen, A ² is oxygen, when X is -CONR ⁵ R ^6, R ³ is carboxy, ester, amido road, substituted And is different from a phenyl group optionally substituted at the para position by an oxo-pyrrolidine, a hydroxy, an oxy derivative, an amino, an amino derivative, a methyl, a naphthyl or a halogen atom.
[2" claim-type="Currently amended] The compound according to claim 1, wherein X is
a) -COOR ⁷ or -CONR ⁵ R ⁶ ;
b) -COOR ⁷ or -CONR ⁵ R ⁶ , wherein R ⁵ , R ⁶ and R ⁷ are hydrogen, C 1-4 -alkyl, phenyl or alkylphenyl;
c) carboxy or -CONR ⁵ R ⁶ ;
d) carboxy or -CONR ⁵ R ⁶ , wherein R ⁵ and R ⁶ are preferably hydrogen, C 1-4 -alkyl, phenyl or alkylphenyl;
e) -CONR ⁵ R ^6; or
f) a compound characterized in that the substituents selected from -CONH _2.
[3" claim-type="Currently amended] 2. The compound of claim 1 wherein R &lt; ^{1 &gt;} is
a) hydrogen, alkyl or aryl;
b) hydrogen, C1-12 alkyl or aryl;
c) hydrogen, lower alkyl or phenyl;
d) methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethyl ethyl, each of which is optionally linked via a methylene bridge, Those substituted by one or more halogen atoms; or
e) ethyl. &lt; / RTI &gt;
[4" claim-type="Currently amended] The method of claim 1 wherein, R ² and R ^2a are independently
a) hydrogen, halogen or alkyl;
b) hydrogen, halogen or lower alkyl;
c) a substituent selected from methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethyl or substituted by one or more halogen atoms thereof, .
[5" claim-type="Currently amended] The method of claim 4, wherein the or at least one of R ² and R ^2a is hydrogen, the compound characterized in that both are hydrogen.
[6" claim-type="Currently amended] The compound of claim 1, wherein R ^3a , R ⁴ and R ^4a are independently
a) hydrogen, alkyl, aryl or aralkyl;
b) hydrogen, methyl, ethyl, phenyl or benzyl;
c) a substituent selected from methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethyl or substituted by one or more halogen atoms thereof, .
[7" claim-type="Currently amended] 7. A compound according to claim 6 wherein at least one of R &lt; ⁴ &gt; and R &lt; ^4a &gt; is hydrogen, or both are hydrogen.
[8" claim-type="Currently amended] 8. The compound according to claim 6 or 7, wherein R &lt; ^{3a &}
a) hydrogen or alkyl;
b) hydrogen or lower alkyl; or
&lt; / RTI &gt; c) hydrogen.
[9" claim-type="Currently amended] The compound according to claim 1, wherein R ³ is
a) hydrogen, C1-12-alkyl each of which is optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy and which is optionally substituted by one or more substituents selected from the group consisting of thio, Carbonyl or oxycarbonyl group and optionally via a C1-4-alkylene bridge); C2-6-alkenyl or -alkynyl, each of which is optionally substituted by one or more halogens; Azido; Cyano; Amido; Carboxy; Thiazolyl, thiazolyl, tetrazolyl, pyrrolidinyl, pyridyl, 1-oxydopyridyl, thiomorpholinyl, benzodioxolyl, furyl, oxazolyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl Or piperazinyl, each of which is optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl and phenyl, and which is bonded directly or via a carbonyl group or a C 1-4 -alkylene bridge to the ring; Naphthyl; Or phenyl, phenylalkyl or phenylalkenyl, each of which is optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl, C 1-6 -alkoxy, C 1-6 alkylthio, amino, azido, Optionally substituted by one or more of the above substituents and is attached to the ring either directly or through an oxy, sulfonyl, sulfonyloxy, carbonyl or carbonyloxy group and optionally a C1-4-alkylene bridge;
b) the same as a) except that alkyl is C1-6-alkyl and the C1-4 alkylene bridge is methylene;
c) Ci-6-alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato, azido, alkoxy, alkylthio, phenylsulfonyl; Nitrooxy; C2-3-alkenyl or -alkynyl; Tetrazolyl, pyridyl, furyl, pyrrolyl, thiazolyl or thienyl each of which is optionally substituted by one or more halogens or acetyl; Phenyl or phenylalkyl each of which is optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl, C 1-6 -alkoxy, amino, azido, phenyl and nitro, , Or sulfonyloxy and optionally C 1-4 -alkylene bridges, especially methylene, to the ring);
d) the same as c) except that the C1-4 alkylene bridges are methylene;
e) methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethyl ethyl or substituted by one or more halogen atoms thereof, hydrogen, or halogen;
f) C1-4-alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato or azido; C2-5-alkenyl or -alkynyl, each of which is optionally substituted by one or more halogens; Thienyl; Or phenyl optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl, C 1-6 haloalkyl or azido; or
g) C1-6-alkyl and C2-6-haloalkenyl.
[10" claim-type="Currently amended] The method of claim 1 wherein, R ⁵ and R ⁶ are independently a,
a) hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl; or
and b) is hydrogen or methyl.
[11" claim-type="Currently amended] 11. The compound of claim 10 wherein at least one of R &lt; ⁵ &gt; and R &lt; ⁶ &gt; is hydrogen, or both are hydrogen.
[12" claim-type="Currently amended] The compound according to claim 1, wherein R ⁷ is
a) hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl, phenyl, benzyl or substituted by one or more halogen atoms thereof;
b) hydrogen, methyl or ethyl; or
&lt; / RTI &gt; c) hydrogen.
[13" claim-type="Currently amended] The compound according to claim 1, wherein R &lt; ⁸ &gt;
a) hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or tert-butyl, 2,2,2-trimethylethyl, phenyl, benzyl or substituted by one or more halogen atoms thereof; or
and b) is hydrogen or methyl.
[14" claim-type="Currently amended] The method according to claim 1,
A ² is oxygen;
X is ^{-CONR 5 R 6, -COOR 7,} -CO-R 8 or CN, and;
R ¹ is hydrogen or alkyl, aryl, halogen, hydroxy, amino, nitro, cyano;
R ² , R ³ and R ⁴ are the same or different and each independently represents hydrogen or a substituent selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, acyl, acyloxy, sulfonyl, Wherein R ³ is an alkylene, alkenyl, alkenyl, alkynyl, alkenyl, alkynyl, alkynyl, arylalkynyl, Each of which is optionally substituted by one or more of halogen, cyano, thiocyano, azido, cyclopropyl, acyl and / or phenyl; Or phenylsulfonyloxy (the phenyl moiety may be substituted by one or more of halogen, alkyl, haloalkyl, alkoxy, nitro, amino and / or phenyl);
R ^2a , R ^3a and R ^4a are hydrogen;
R ⁵ , R ⁶ and R ⁷ are the same or different and each is independently hydrogen, hydroxy, alkyl, aryl, heterocycle or oxy derivative;
R &lt; ⁸ &gt; is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, heterocycle, alkylthio or thio derivative.
[15" claim-type="Currently amended] 15. The method of claim 14,
R ¹ is methyl, ethyl, propyl, isopropyl, butyl or isobutyl;
R ² and R ⁴ are independently hydrogen or halogen or methyl, ethyl, propyl, isopropyl, butyl, isobutyl;
R ³ is selected from the group consisting of C 1 -5 alkyl, C 2 -5 alkenyl, C 2 -C 5 alkynyl, cyclopropyl, azido each of which is optionally substituted by halogen, cyano, thiocyano, azido, alkylthio, cyclopropyl, Or phenyl; Phenyl; Phenylsulfonyl; Wherein the phenyl moiety may be substituted by one or more of halogen, alkyl, haloalkyl, alkoxy, nitro, amino, and / or phenyl; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; Most preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl;
X is selected from the compounds as claimed -COOH, -COOMe, -COOEt, -COOtBu or -CONH _2.
[16" claim-type="Currently amended] 16. The method of claim 15,
R ¹ is methyl, ethyl or n-propyl;
R ² and R ⁴ are each hydrogen;
Compound characterized in that X is -CONH _2.
[17" claim-type="Currently amended] The method according to claim 1,
X is _{^{-CA 1 NH 2, -CA 1 NHCH}} 3 or -CA ¹ N (CH _{3) 2,} and;
R &lt; ¹ &gt; is alkyl or phenyl;
R ³ is alkyl, alkenyl, alkynyl, cyano, isothiocyanato, ether, carboxyl, amido, aryl or heterocycle,
R ³ is CH ₂ R ¹⁰ wherein R ¹⁰ is hydrogen, cycloalkyl, oxyester, oxyalkylsulfonyl, oxyarylsulfonyl, aminoalkylsulfonyl, aminoarylsulfonyl, nitrooxy, cyano, isothiocyanate Alkylthio, alkylsulfinyl, alkylsulfonyl, heterocycle, aryloxy, alkoxy or trifluoroethyl; R &lt; 2 &gt;
R &lt; ^3a &gt; is hydrogen, alkyl or aryl;
R ³ and R ^3a form a cycloalkyl;
R ² , R ^2a , R ⁴ and R ^4a are each hydrogen.
[18" claim-type="Currently amended] The method according to claim 1,
R &lt; ¹ &gt; is alkyl;
R ² , R ^2a , R ^3a and R ^4a are each hydrogen;
R ³ is hydrogen; C1-12-alkyl optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy, and which is either directly or via a thio, sulfinyl, sulfonyl, carbonyl or oxycarbonyl group, and Optionally bonded to the ring via a C1-4-alkylene bridge); C2-6-alkenyl or -alkynyl, each of which is optionally substituted by one or more halogens; Azido; Cyano; Amido; Carboxy; Thiazolyl, thiazolyl, tetrazolyl, pyrrolidinyl, pyridyl, 1-oxydopyridyl, thiomorpholinyl, benzodioxolyl, furyl, oxazolyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl Or piperazinyl, each of which is optionally substituted by one or more substituents selected from halogen, C 1-6 -alkyl and phenyl, and which is bonded directly or via a carbonyl group or a C 1-4 -alkylene bridge to the ring; Naphthyl; Or phenyl, phenylalkyl or phenylalkenyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-6-alkyl, C1-6 haloalkyl, C1-6-alkoxy, C1-6-alkylthio, amino, And is bonded directly to the ring via an oxy, sulfonyl, sulfonyloxy, carbonyl or carbonyloxy group and optionally further C 1-4 -alkylene bridges;
R &lt; ^3a &gt; is hydrogen or C1-4-alkyl;
R ⁴ and R ^4a are, independently, hydrogen, C ^1-4 -alkyl, phenyl or benzyl.
[19" claim-type="Currently amended] ^19. The compound of claim 18, wherein R &lt; ¹ &gt; is a) C1-12-alkyl; b) Ci-6-alkyl; Or c) ethyl,
RTI ID = 0.0 &gt; Cl4-alkylene &lt; / RTI &gt; bridges are methylene.
[20" claim-type="Currently amended] The method of claim 1 wherein is present in the racemic form, X is -CONR ⁵ R ⁶ and when, R ¹ is hydrogen, methyl, ethyl or propyl, the substituent on the pyrrolidine ring P is mono-, di-or tri- Methyl, or mono-ethyl.
[21" claim-type="Currently amended] 2. A compound according to claim 1, which is in racemic form, wherein X is -CONR ⁵ R ⁶ and R ¹ is hydrogen, an unsubstituted C ^1-6 -alkyl, a C 2-6 -alkenyl or an alkynyl, Alkyl, the substituents on the ring are each an unsubstituted group other than alkyl, alkenyl or alkynyl.
[22" claim-type="Currently amended] The method according to claim 1,
X is -CA ¹ NH _2, and;
R &^lt; ¹ &gt; is hydrogen;
R <^3> is methyl, iodomethyl, C2-6-alkyl optionally substituted by one to five halogen atoms, vinyl optionally substituted by one or two methyl and / or one to three halogen atoms , C1-4-alkyl, phenyl or acetylene optionally substituted by halogen;
R &lt; ^3a &gt; is hydrogen or halogen, preferably fluorine;
R ² , R ^2a , R ⁴ and R ^4a are each hydrogen,
Racemic or enantiomerically enriched, preferably pure enantiomer.
[23" claim-type="Currently amended] The method according to claim 1,
X is -CA ¹ NH _2, and;
R &^lt; ¹ &gt; is hydrogen;
R ³ is azido, oxinitro, C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl optionally substituted by one to six halogen atoms;
R &lt; ^3a &gt; is hydrogen or halogen, preferably fluorine;
R ² , R ^2a , R ⁴ and R ^4a are each hydrogen,
Racemic or enantiomerically enriched, preferably pure enantiomer.
[24" claim-type="Currently amended] 2. The compound of claim 1, wherein A &^lt; ¹ &gt; and A &lt; ² &gt; are oxygen; R &lt; ¹ &gt; is ethyl; X is -CONH ₂ and; R ³ is n-propyl or 2,2-difluorovinyl, and all other substituents are hydrogen.
[25" claim-type="Currently amended] A compound of the formula &lt; RTI ID = 0.0 &gt;

Wherein X, R ¹ , R ² , R ³ , R ⁴ , R ^2a , R ^3a and R ^4a are as defined in claim 1,
Q ¹ together with the oxygen to which Q ¹ is attached forms a leaving group.
[26" claim-type="Currently amended] 26. The compound of claim 25, wherein Q &lt; ¹ &gt; is a) alkyl; Or b) a linear or branched &lt; RTI ID = 0.0 &gt; Cl 4-alkyl. &Lt; / RTI &gt;
[27" claim-type="Currently amended] 26. Compounds according to any one of claims 1 to 26, characterized in that they are pure enantiomers.
[28" claim-type="Currently amended] 27. Compounds according to any one of claims 1 to 27, characterized in that when the carbon atom to which R &lt; ^{1 &gt;} is bonded is asymmetrical, it has an "S" -structure.
[29" claim-type="Currently amended] Compound No. 8, 9, 10, 22, 23, 27, 30, 31, 32, 33, 38, 40, 41, 43, 46, 47, 49, 64, 71, 86, 87, 88, 92, 93, 95, 96, 98, 100, 103, 105, 110, 119, 127, 142, 146, 149, 151, 152, 156, 157, 158, 159, 162, 163, 198, 200, 201, 204, 205, 207, 209, 209, 209, 209, 209, 234, 250, 251, 252, 264, 265, 267, 304, 306, 350, 351, 226, 228, 229, A compound selected from AA 1, AA 2, AA 3, AA 4 and AA 5, or a pharmaceutically acceptable salt thereof.
[30" claim-type="Currently amended] (2S) -2 - [(4S) -4- (2,2-difluorovinyl) -2-oxopyrrolidinyl] butanamide or a pharmaceutically acceptable salt thereof.
[31" claim-type="Currently amended] (4R) and (4S) diastereomers of (2S) -2- [2-oxo-4-propylpyrrolidinyl] butanamide or a pharmaceutically acceptable salt thereof.
[32" claim-type="Currently amended] 31. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 31 and a pharmaceutically acceptable diluent or carrier.
[33" claim-type="Currently amended] (Including but not limited to epilepsy, epilepsy, seizure disorders, convulsions, and bipolar disorder, manic depression, anxiety, migraine, tricuspid and other neuralgia, chronic pain, neuropathic pain, cerebral infarction, cardiac neglect, stroke, chronic sinus rhythm, epilepsy and other movement disorders, neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, rigorous, Parkinson's and other neurological diseases including degenerative diseases, bronchial asthma, persistent asthma and allergic bronchitis, The use of a compound according to any one of claims 1 to 32 for the manufacture of a medicament for the treatment of asthma syndrome, bronchial hyperresponsiveness, bronchospastic syndromes and allergic and vasomotor rhinitis and rhinoconjunctivitis. Usage.
[34" claim-type="Currently amended] Epileptic, epileptic, convulsive, and bipolar disorder, manic, depression, anxiety, migraine, tricuspid and other neuralgia, epilepsy, epilepsy, and bipolar disorder, including the administration of one or more compounds according to any one of claims 1-33 of the therapeutic dose. Cerebral hemorrhage, amyotrophic lateral sclerosis, rigidity, Parkinson &apos; s disease, and the like, including, but not limited to, chronic pain, neuropathic pain, cerebral infarction, cardiac anomalies, myalgia, cocaine abuse, stroke, In mammals requiring treatment of other neurological diseases including degenerative diseases, bronchial asthma, persistent asthma and allergic bronchitis, asthma syndrome, bronchial hyperresponsiveness and bronchospastic syndrome and allergic and vasomotor rhinitis and rhinoconjunctivitis, A method for treating a disease.
[35" claim-type="Currently amended] Chronic pain, neuropathic pain, cerebral hemorrhage, cardiac anomalies, myalgia, cocaine abuse, strokes, dyspepsia, epilepsy, epilepsy, seizure disorders, convulsions, and bipolar disorders, manic, depression, anxiety, migraine, Asthma, bronchial asthma, persistent asthma and allergic bronchitis, asthma syndrome, asthma, asthma, asthma, chronic obstructive pulmonary disease and other neurological disorders including neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, For the manufacture of a medicament for the treatment of bronchial hyperresponsiveness and bronchospastic syndrome and allergic and vasomotor rhinitis and rhinoconjunctivitis,
Each substituent is as defined in claim 1, with the proviso that at least one of R ² , R ³ , R ⁴ , R ^2a , R ^3a and R ^4a is hydrogen; When the compound is a mixture of all possible isomers, X is -CONR ⁵ R ⁶ , A ² is oxygen and R ¹ is hydrogen, methyl, ethyl or propyl, the substituent on the pyrrolidine ring is mono-, Use of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein R is a group other than tri-methyl, or mono-ethyl.
[36" claim-type="Currently amended] Each substituent is as defined in claim 1, with the proviso that at least one of R ² , R ³ , R ⁴ , R ^2a , R ^3a and R ^4a is hydrogen; When the compound is a mixture of all possible isomers, X is -CONR ⁵ R ⁶ , A ² is oxygen and R ¹ is hydrogen, methyl, ethyl or propyl, the substituent on the pyrrolidine ring is mono-, Comprising administering a therapeutical dose of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof, wherein R &lt; 1 &gt; is methyl,
Chronic pain, neuropathic pain, cerebral hemorrhage, cardiac anomalies, myalgia, cocaine abuse, strokes, dyspepsia, epilepsy, epilepsy, seizure disorders, convulsions, and bipolar disorders, manic, depression, anxiety, migraine, Asthma, bronchial asthma, persistent asthma and allergic bronchitis, asthma syndrome, asthma, asthma, asthma, chronic obstructive pulmonary disease and other neurological disorders including neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, Bronchial hyperresponsiveness, bronchospastic syndrome and allergic and vasomotor rhinitis and rhinoconjunctivitis.
[37" claim-type="Currently amended] 36. Use according to claim 35, characterized in that the compound of formula (I) is according to any one of claims 29 to 31.
[38" claim-type="Currently amended] 37. The method of claim 36, wherein the compound of formula I is a compound according to any one of claims 29-31.
[39" claim-type="Currently amended] Use according to claims 35 or 37, characterized in that the disease to be treated is epilepsy, neuropathic pain, bipolar disorder or migraine, or a method according to claim 36 or 38.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US9944601B2|2018-04-17|aryl cyclopropylamine compounds as LSD1 inhibitors

---

ES2442905T3|2014-02-14|Oxazine derivatives and their use in the treatment of neurological disorders

---

JP6289485B2|2018-03-07|Heteroaryl inhibitors of PDE4

---

KR101192861B1|2012-10-19|Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors

---

JP5767178B2|2015-08-19|Novel 1-aryl-3-azabicyclo [3.1.0] hexanes: preparation and use in the treatment of neuropsychiatric disorders

---

EP0930298B1|2002-12-18|Fluorinated 1,4-disubstituted piperidine derivatives

---

US6727275B2|2004-04-27|Pyrrolidinone derivatives

---

US7012085B2|2006-03-14|1,3 disubstituted pyrrolidines as α-2-adrenoceptor antagonists

---

KR100258373B1|2000-07-01|Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present

---

KR20150110784A|2015-10-02|Spiro-lactam nmda receptor modulators and uses thereof

---

CA2570197C|2013-09-10|Nk1 antagonists

---

US6710064B2|2004-03-23|Hydantoin compounds useful as anti-inflammatory agents

---

ES2307175T3|2008-11-16|Derivatives of adamantil-pirrolidin-2-ona as inhibitors dela 11-beta-hydroxiesteroid-dehydrogenase.

---

US7964593B2|2011-06-21|Indolone-acetamide derivatives, processes for preparing them and their uses

---

US5637602A|1997-06-10|Pyrrolidine and thiazolidine derivatives, their preparation and drugs containing same

---

KR100437972B1|2004-07-02|Pyrrolidinone Derivatives, Their Preparation and Pharmaceutical Composition Comprising the Same

---

US7615572B2|2009-11-10|Pyrrole and pyrazole DAAO inhibitors

---

US5633270A|1997-05-27|Thiazolidine derivatives, preparation thereof and drugs containing samem

---

EP0338331B1|1992-10-21|1,3 disubstituted pyrrolidines

---

ES2528948T3|2015-02-13|Pyrrolidinone carboxamide derivatives as R-quemerin modulators |

---

ES2323313T3|2009-07-13|Imidazol derivatives, procedures to prepare them and their uses.

---

US20100222326A1|2010-09-02|New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders

---

US7579370B2|2009-08-25|Fused heterocycles

---

ES2230846T3|2005-05-01|4-phenylpiperidins for the treatment of prurite dermatosis.

---

KR100329450B1|2002-10-04|Novel heterocyclic compounds, preparation methods thereof, and pharmaceutical compositions comprising the same

同族专利:

---

公开号 | 公开日

---

EP1263727B1|2004-11-17|

---

HU0204526A2|2003-04-28|

---

RO121597B1|2007-12-28|

---

CO5271667A1|2003-04-30|

---

SA1275B1|2006-09-19|

---

KR20020075927A|2002-10-07|

---

CZ304420B6|2014-04-30|

---

PL365159A1|2004-12-27|

---

AT445597T|2009-10-15|

---

WO2001062726A3|2002-01-17|

---

NO20023995L|2002-10-21|

---

IS2176B|2006-12-15|

---

DK1452524T3|2010-03-01|

---

BG65803B1|2009-12-31|

---

RS50455B|2010-03-02|

---

PT1452524E|2010-01-18|

---

ES2355140T3|2011-03-23|

---

KR100816185B1|2008-03-21|

---

HU230270B1|2015-11-30|

---

JP2003528828A|2003-09-30|

---

MXPA02008206A|2004-04-05|

---

US20100222576A1|2010-09-02|

---

IL150842D0|2003-02-12|

---

BR0108657A|2003-04-29|

---

JP4081275B2|2008-04-23|

---

RU2292336C2|2007-01-27|

---

US20040192757A1|2004-09-30|

---

NO2016005I2|2016-03-08|

---

BE2016C012I2|2020-01-30|

---

NO324485B1|2007-10-29|

---

EP1452524A1|2004-09-01|

---

IL166768A|2010-04-15|

---

EG24375A|2009-03-19|

---

EP1265862B1|2005-09-21|

---

PL213669B1|2013-04-30|

---

DK1265862T3|2006-01-30|

---

YU63102A|2005-09-19|

---

IL166768D0|2006-01-15|

---

HUS1600017I1|2020-02-28|

---

KR20050091112A|2005-09-14|

---

RO121559B1|2007-11-30|

---

NO20053645L|2002-10-22|

---

CA2401033A1|2001-08-30|

---

CN1680314A|2005-10-12|

---

NO20023997D0|2002-08-22|

---

SA1463B1|2006-10-29|

---

RU2005125645A|2007-02-20|

---

AU2005200717A1|2005-03-17|

---

AU5214401A|2001-09-03|

---

BG65923B1|2010-05-31|

---

IS7923A|2005-06-29|

---

CN1404469A|2003-03-19|

---

BG109297A|2006-06-30|

---

KR100759145B1|2007-09-14|

---

NL300815I2|2016-07-27|

---

PL210121B1|2011-12-30|

---

US8034958B2|2011-10-11|

---

NO2016005I1|2016-03-08|

---

SI1265862T1|2006-02-28|

---

US20120035239A1|2012-02-09|

---

DE60143493D1|2010-12-30|

---

IS7922A|2005-06-29|

---

NZ520448A|2004-03-26|

---

PT1447399E|2006-09-29|

---

US20050171187A1|2005-08-04|

---

MY139420A|2009-09-30|

---

BRPI0108664B1|2016-07-26|

---

IL170181A|2010-11-30|

---

NO20023997L|2002-10-22|

---

CA2401048C|2009-01-20|

---

EP1577296A1|2005-09-21|

---

HU0300196A3|2005-10-28|

---

EP1477478A3|2004-11-24|

---

AT282592T|2004-12-15|

---

CN1740150A|2006-03-01|

---

AU2005200717B2|2007-05-17|

---

DK1447399T3|2006-08-28|

---

US7358276B2|2008-04-15|

---

AU7389601A|2001-09-12|

---

EP1577295A1|2005-09-21|

---

JP2003523996A|2003-08-12|

---

CZ304702B6|2014-09-03|

---

US20050171188A1|2005-08-04|

---

EP1447399B1|2006-05-03|

---

CA2401033C|2008-07-29|

---

AT488500T|2010-12-15|

---

US7692028B2|2010-04-06|

---

NO324051B1|2007-08-06|

---

AU2005200718A1|2005-03-17|

---

PL212197B1|2012-08-31|

---

IS6481A|2002-07-23|

---

WO2001064637A1|2001-09-07|

---

MY140593A|2009-12-31|

---

AU2005200718B2|2007-05-24|

---

ZA200205837B|2003-11-04|

---

IS2754B|2011-09-15|

---

CN1303066C|2007-03-07|

---

DE60113514D1|2005-10-27|

---

KR100720784B1|2007-05-23|

---

TW200626545A|2006-08-01|

---

US20040087646A1|2004-05-06|

---

LTC1265862I2|2017-06-12|

---

DE60107216T2|2005-11-03|

---

CN1404470A|2003-03-19|

---

BR0108664A|2003-04-29|

---

ZA200205671B|2003-11-10|

---

MXPA02008056A|2004-08-12|

---

AU2001252144B2|2005-04-28|

---

ME00595B|2011-12-20|

---

BG107016A|2003-04-30|

---

US20030040631A1|2003-02-27|

---

IS2119B|2006-06-15|

---

EP1477478A2|2004-11-17|

---

IS7920A|2005-06-29|

---

US20050159475A1|2005-07-21|

---

CZ20022849A3|2003-02-12|

---

DE60119397D1|2006-06-08|

---

EP1447399B9|2006-10-18|

---

RU2355680C2|2009-05-20|

---

GB0004297D0|2000-04-12|

---

CN1208319C|2005-06-29|

---

TW200626544A|2006-08-01|

---

KR100681580B1|2007-02-09|

---

EP1263727A1|2002-12-11|

---

MY138966A|2008-08-28|

---

HU229514B1|2014-01-28|

---

US6806287B2|2004-10-19|

---

US7217826B2|2007-05-15|

---

JP4121744B2|2008-07-23|

---

JP2007182459A|2007-07-19|

---

YU63202A|2005-09-19|

---

US20040092576A1|2004-05-13|

---

US20030120080A1|2003-06-26|

---

KR20050090090A|2005-09-12|

---

HU0300196A2|2003-06-28|

---

NO20053644L|2002-10-22|

---

DE60107216D1|2004-12-23|

---

BG65783B1|2009-11-30|

---

DE60113514T2|2006-05-18|

---

JP4938259B2|2012-05-23|

---

ES2334998T3|2010-03-18|

---

US6969770B2|2005-11-29|

---

IS7919A|2005-06-29|

---

IS7918A|2005-06-29|

---

WO2001062726A2|2001-08-30|

---

US20080097109A1|2008-04-24|

---

US8492416B2|2013-07-23|

---

MEP6109A|2011-12-20|

---

HU0500902D0|2005-12-28|

---

US6713635B2|2004-03-30|

---

RU2006125756A|2008-01-27|

---

AT304999T|2005-10-15|

---

US6911461B2|2005-06-28|

---

DE60140222D1|2009-11-26|

---

EP1477478B1|2010-11-17|

---

IL150842A|2008-06-05|

---

CA2401048A1|2001-09-07|

---

ES2248307T3|2006-03-16|

---

PL359388A1|2004-08-23|

---

ES2264060T3|2006-12-16|

---

HK1052516A1|2006-02-10|

---

RU2291860C3|2017-11-16|

---

IS7921A|2005-06-29|

---

EP1265862A2|2002-12-18|

---

AU2001252144C1|2008-03-20|

---

BG107004A|2003-04-30|

---

EP1604979A1|2005-12-14|

---

LU92993I2|2016-05-11|

---

US6784197B2|2004-08-31|

---

CU23293B7|2008-06-30|

---

CY1109718T1|2014-08-13|

---

HK1052695A1|2005-05-06|

---

RU2291860C2|2007-01-20|

---

AT325093T|2006-06-15|

---

EP1447399A1|2004-08-18|

---

IL150757D0|2003-02-12|

---

CZ20022850A3|2003-02-12|

---

RS50454B|2010-03-02|

---

US20040116507A1|2004-06-17|

---

ES2231501T3|2005-05-16|

---

JP2006022108A|2006-01-26|

---

HU0204526A3|2005-03-29|

---

AU778510B2|2004-12-09|

---

CU23201A3|2007-04-06|

---

CN1740151A|2006-03-01|

---

IS6472A|2002-07-16|

---

DE60119397T2|2007-04-19|

---

RU2005125569A|2007-02-20|

---

RU2002124865A|2004-01-10|

---

JP4769756B2|2011-09-07|

---

EP1452524B1|2009-10-14|

---

NO20023995D0|2002-08-22|

---

JP2006022107A|2006-01-26|

---

CO5280059A1|2003-05-30|

---

CN1179944C|2004-12-15|

---

US6858740B2|2005-02-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2000-02-23|Priority to GBGB0004297.8A

---

2000-02-23|Priority to GB0004297.8

---

2001-02-21|Application filed by 유씨비 소시에떼아노님

---

2002-10-07|Publication of KR20020075926A

---

2008-03-21|Application granted

---

2008-03-21|Publication of KR100816185B1

---

2017-12-20|First worldwide family litigation filed

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB0004297.8A|GB0004297D0|2000-02-23|2000-02-23|2-oxo-1 pyrrolidine derivatives process for preparing them and their uses|

---

GB0004297.8|2000-02-23|